WO2020192570A1 - 小分子pd-1/pd-l1抑制剂、其与pd-l1抗体的药物组合物及其应用 - Google Patents
小分子pd-1/pd-l1抑制剂、其与pd-l1抗体的药物组合物及其应用 Download PDFInfo
- Publication number
- WO2020192570A1 WO2020192570A1 PCT/CN2020/080362 CN2020080362W WO2020192570A1 WO 2020192570 A1 WO2020192570 A1 WO 2020192570A1 CN 2020080362 W CN2020080362 W CN 2020080362W WO 2020192570 A1 WO2020192570 A1 WO 2020192570A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- ring
- group
- unsubstituted
- alkyl
- Prior art date
Links
- 150000003384 small molecules Chemical class 0.000 title claims abstract description 114
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 70
- 239000003112 inhibitor Substances 0.000 title abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 53
- -1 aromatic ethylene derivative Chemical class 0.000 claims abstract description 30
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 102000008096 B7-H1 Antigen Human genes 0.000 claims abstract description 13
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 237
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 claims description 105
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 claims description 105
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 72
- 125000000217 alkyl group Chemical group 0.000 claims description 69
- 229910052736 halogen Inorganic materials 0.000 claims description 62
- 125000001424 substituent group Chemical group 0.000 claims description 62
- 150000002367 halogens Chemical class 0.000 claims description 61
- 125000001072 heteroaryl group Chemical group 0.000 claims description 53
- 125000005842 heteroatom Chemical group 0.000 claims description 47
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 claims description 46
- 125000003545 alkoxy group Chemical group 0.000 claims description 46
- 229940127204 compound 29 Drugs 0.000 claims description 46
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 43
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 41
- 238000002360 preparation method Methods 0.000 claims description 41
- 229950009791 durvalumab Drugs 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 40
- 125000004432 carbon atom Chemical group C* 0.000 claims description 38
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 34
- 125000004414 alkyl thio group Chemical group 0.000 claims description 32
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 31
- 125000002837 carbocyclic group Chemical group 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 23
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical group C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 22
- 229920002554 vinyl polymer Polymers 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 238000002347 injection Methods 0.000 claims description 20
- 239000007924 injection Substances 0.000 claims description 20
- 239000000651 prodrug Substances 0.000 claims description 19
- 229940002612 prodrug Drugs 0.000 claims description 19
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 18
- 229910052805 deuterium Inorganic materials 0.000 claims description 18
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- 238000002474 experimental method Methods 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- 125000003368 amide group Chemical group 0.000 claims description 13
- 125000003277 amino group Chemical group 0.000 claims description 13
- 125000004185 ester group Chemical group 0.000 claims description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 12
- 239000002207 metabolite Substances 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 230000002503 metabolic effect Effects 0.000 claims description 9
- 239000002243 precursor Substances 0.000 claims description 9
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 8
- 229960003852 atezolizumab Drugs 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 229950002916 avelumab Drugs 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 4
- 239000006186 oral dosage form Substances 0.000 claims description 4
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 125000002619 bicyclic group Chemical group 0.000 claims description 3
- 229940121420 cemiplimab Drugs 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical group C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 claims description 2
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical group C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 claims description 2
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical group C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 claims description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical group N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 claims description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 2
- ZKAMEFMDQNTDFK-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyrazine Chemical group C1=CN=C2NC=NC2=N1 ZKAMEFMDQNTDFK-UHFFFAOYSA-N 0.000 claims description 2
- YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical group C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 claims description 2
- HRCMXYXVAWHBTH-UHFFFAOYSA-N 2,3-dihydro-1,3-benzoxazole Chemical group C1=CC=C2OCNC2=C1 HRCMXYXVAWHBTH-UHFFFAOYSA-N 0.000 claims description 2
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical group C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 claims description 2
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical group C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 claims description 2
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical group C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 claims description 2
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical group N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 claims description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical group C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 claims description 2
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical group C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 claims description 2
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical group C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims description 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- MXMZCLLIUQEKSN-UHFFFAOYSA-N benzimidazoline Chemical group C1=CC=C2NCNC2=C1 MXMZCLLIUQEKSN-UHFFFAOYSA-N 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims description 2
- 125000005048 dihydroisoxazolyl group Chemical group O1N(CC=C1)* 0.000 claims description 2
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 2
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 claims description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000006606 n-butoxy group Chemical group 0.000 claims description 2
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical group C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 1
- OKEAMBAZBICIFP-UHFFFAOYSA-N 3-oxido-2,1,3-benzoxadiazol-3-ium Chemical group C1=CC=CC2=[N+]([O-])ON=C21 OKEAMBAZBICIFP-UHFFFAOYSA-N 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical group C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 269
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 201
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 177
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 177
- 238000006243 chemical reaction Methods 0.000 description 142
- 239000000243 solution Substances 0.000 description 139
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 107
- 230000002829 reductive effect Effects 0.000 description 97
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 92
- 238000003786 synthesis reaction Methods 0.000 description 89
- 230000015572 biosynthetic process Effects 0.000 description 88
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 68
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 64
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 61
- 239000012071 phase Substances 0.000 description 60
- 238000005481 NMR spectroscopy Methods 0.000 description 51
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 45
- 239000012074 organic phase Substances 0.000 description 45
- 239000011259 mixed solution Substances 0.000 description 44
- 239000003208 petroleum Substances 0.000 description 44
- 238000010898 silica gel chromatography Methods 0.000 description 42
- 239000002904 solvent Substances 0.000 description 42
- 241000699670 Mus sp. Species 0.000 description 40
- 238000003756 stirring Methods 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 238000000746 purification Methods 0.000 description 35
- 229960000583 acetic acid Drugs 0.000 description 34
- 239000012362 glacial acetic acid Substances 0.000 description 34
- 239000007787 solid Substances 0.000 description 34
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 34
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 33
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 33
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 32
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 235000002639 sodium chloride Nutrition 0.000 description 26
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 238000000034 method Methods 0.000 description 21
- 239000000725 suspension Substances 0.000 description 21
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 19
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 19
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 19
- 239000001099 ammonium carbonate Substances 0.000 description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 239000002552 dosage form Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 17
- 229910000160 potassium phosphate Inorganic materials 0.000 description 17
- 235000011009 potassium phosphates Nutrition 0.000 description 17
- CDUUKBXTEOFITR-UHFFFAOYSA-N 2-methylserine zwitterion Chemical compound OCC([NH3+])(C)C([O-])=O CDUUKBXTEOFITR-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 238000004809 thin layer chromatography Methods 0.000 description 16
- CDUUKBXTEOFITR-BYPYZUCNSA-N 2-methyl-L-serine Chemical compound OC[C@@]([NH3+])(C)C([O-])=O CDUUKBXTEOFITR-BYPYZUCNSA-N 0.000 description 15
- 229910000029 sodium carbonate Inorganic materials 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- 239000003960 organic solvent Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 229910000033 sodium borohydride Inorganic materials 0.000 description 12
- 239000012279 sodium borohydride Substances 0.000 description 12
- 238000001816 cooling Methods 0.000 description 11
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 11
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 10
- JPJGNZQDELRZGE-UHFFFAOYSA-N (phenyl-$l^{2}-phosphanyl)benzene Chemical compound C=1C=CC=CC=1[P]C1=CC=CC=C1 JPJGNZQDELRZGE-UHFFFAOYSA-N 0.000 description 10
- 239000007929 subcutaneous injection Substances 0.000 description 10
- 238000010254 subcutaneous injection Methods 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 229910052763 palladium Inorganic materials 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- 238000010253 intravenous injection Methods 0.000 description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 238000006268 reductive amination reaction Methods 0.000 description 8
- 229960001153 serine Drugs 0.000 description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- ADEBJOYGWGBKQH-BQYQJAHWSA-N 2-[[3-[(E)-2-[3-(4-fluorophenyl)-2-methylphenyl]ethenyl]-4-(trifluoromethyl)phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid Chemical compound FC1=CC=C(C=C1)C1=C(C(=CC=C1)/C=C/C=1C=C(CNC(C(=O)O)(CO)C)C=CC=1C(F)(F)F)C ADEBJOYGWGBKQH-BQYQJAHWSA-N 0.000 description 6
- UZRXBDTYEDVURY-ZHACJKMWSA-N 3-hydroxy-2-methyl-2-[[4-methyl-3-[(E)-2-[2-methyl-3-(4-methylsulfanylphenyl)phenyl]ethenyl]phenyl]methylamino]propanoic acid Chemical compound CSC1=CC=C(C=C1)C1=C(C(=CC=C1)/C=C/C=1C=C(CNC(C(=O)O)(CO)C)C=CC=1C)C UZRXBDTYEDVURY-ZHACJKMWSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- GJFHGYSJILBUNY-MDZDMXLPSA-N 2-[[3-[(E)-2-[3-(4-fluorophenyl)-2-methylphenyl]ethenyl]-4-methylphenyl]methylamino]-3-hydroxy-2-methylpropanoic acid Chemical compound FC1=CC=C(C=C1)C1=C(C(=CC=C1)/C=C/C=1C=C(CNC(C(=O)O)(CO)C)C=CC=1C)C GJFHGYSJILBUNY-MDZDMXLPSA-N 0.000 description 5
- 0 C*C1CCCC1 Chemical compound C*C1CCCC1 0.000 description 5
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 5
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 239000008297 liquid dosage form Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- REOGRYNPVMUXEZ-BUHFOSPRSA-N 3-hydroxy-2-methyl-2-[[4-methyl-3-[(E)-2-[2-methyl-3-(3-methylphenyl)phenyl]ethenyl]phenyl]methylamino]propanoic acid Chemical compound CC=1C=C(C=CC=1)C1=C(C(=CC=C1)/C=C/C=1C=C(CNC(C(=O)O)(CO)C)C=CC=1C)C REOGRYNPVMUXEZ-BUHFOSPRSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- ZRPDXDBGEYHEBJ-UHFFFAOYSA-N alpha-(hydroxymethyl)serine Chemical compound OCC(N)(CO)C(O)=O ZRPDXDBGEYHEBJ-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 4
- 229940126086 compound 21 Drugs 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 102000048776 human CD274 Human genes 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- KNXQDJCZSVHEIW-UHFFFAOYSA-N (3-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1 KNXQDJCZSVHEIW-UHFFFAOYSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
- MWYYNBYTVFKXSD-UHFFFAOYSA-N 3-bromo-4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1Br MWYYNBYTVFKXSD-UHFFFAOYSA-N 0.000 description 3
- DPGSPRJLAZGUBQ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane Substances CC1(C)OB(C=C)OC1(C)C DPGSPRJLAZGUBQ-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 3
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 3
- DATPFTPVGIHCCM-UHFFFAOYSA-N CCNC(C)C(O)=O Chemical compound CCNC(C)C(O)=O DATPFTPVGIHCCM-UHFFFAOYSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 229940126639 Compound 33 Drugs 0.000 description 3
- 229940127007 Compound 39 Drugs 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical class [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 239000012271 PD-L1 inhibitor Substances 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940125644 antibody drug Drugs 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 3
- 235000013877 carbamide Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940125833 compound 23 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 229940125846 compound 25 Drugs 0.000 description 3
- 229940125851 compound 27 Drugs 0.000 description 3
- 229940125877 compound 31 Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000004210 ether based solvent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 3
- 229960001381 glipizide Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229940100692 oral suspension Drugs 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- FNMQRLOQTLZYJI-MOGHOSLNSA-N (2S)-2-[[3-[(E)-2-[3-(5-fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]ethenyl]-4-methylphenyl]methylamino]-3-hydroxy-2-methylpropanoic acid Chemical compound FC1=C(C=CC=2OCCOC=21)C=1C(=C(/C=C/C=2C=C(CN[C@](C(=O)O)(CO)C)C=CC=2C)C=CC=1)C FNMQRLOQTLZYJI-MOGHOSLNSA-N 0.000 description 2
- ATGZFDUWDZOLOS-RTHBMQBDSA-N (2S)-3-hydroxy-2-methyl-2-[[4-methyl-3-[(E)-2-(2-methyl-3-phenylphenyl)ethenyl]phenyl]methylamino]propanoic acid Chemical compound CC1=C(C=CC=C1/C=C/C=1C=C(CN[C@](C(=O)O)(CO)C)C=CC=1C)C1=CC=CC=C1 ATGZFDUWDZOLOS-RTHBMQBDSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- RHSYGYQURQDAQE-BQYQJAHWSA-N 2-[[3-[(E)-2-[3-(4-chlorophenyl)-2-methylphenyl]ethenyl]-4-(trifluoromethyl)phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid Chemical compound ClC1=CC=C(C=C1)C1=C(C(=CC=C1)/C=C/C=1C=C(CNC(C(=O)O)(CO)C)C=CC=1C(F)(F)F)C RHSYGYQURQDAQE-BQYQJAHWSA-N 0.000 description 2
- CDUUKBXTEOFITR-SCSAIBSYSA-N 2-methyl-D-serine Chemical compound OC[C@](N)(C)C(O)=O CDUUKBXTEOFITR-SCSAIBSYSA-N 0.000 description 2
- QCTYBSCOTXUACU-ZHACJKMWSA-N 3-hydroxy-2-[[3-[(E)-2-[3-(4-methoxyphenyl)-2-methylphenyl]ethenyl]-4-methylphenyl]methylamino]-2-methylpropanoic acid Chemical compound COC1=CC=C(C=C1)C1=C(C(=CC=C1)/C=C/C=1C=C(CNC(C(=O)O)(CO)C)C=CC=1C)C QCTYBSCOTXUACU-ZHACJKMWSA-N 0.000 description 2
- DXLJHRBVTXPDAX-UHFFFAOYSA-N 3-hydroxy-2-[[3-[2-(2-methyl-3-phenylphenyl)ethyl]-4-(trifluoromethyl)phenyl]methylamino]propanoic acid Chemical compound CC1=C(C=CC=C1CCC=1C=C(CNC(C(=O)O)CO)C=CC=1C(F)(F)F)C1=CC=CC=C1 DXLJHRBVTXPDAX-UHFFFAOYSA-N 0.000 description 2
- ATGZFDUWDZOLOS-CCEZHUSRSA-N 3-hydroxy-2-methyl-2-[[4-methyl-3-[(E)-2-(2-methyl-3-phenylphenyl)ethenyl]phenyl]methylamino]propanoic acid Chemical compound CC1=C(C=CC=C1/C=C/C=1C=C(CNC(C(=O)O)(CO)C)C=CC=1C)C1=CC=CC=C1 ATGZFDUWDZOLOS-CCEZHUSRSA-N 0.000 description 2
- MINMDCMSHDBHKG-UHFFFAOYSA-N 4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-5-methyl-1,3-thiazol-2-yl]morpholine Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(=C(S1)C)N=C1N1CCOCC1 MINMDCMSHDBHKG-UHFFFAOYSA-N 0.000 description 2
- FXPMFQUOGYGTAM-UHFFFAOYSA-N 6-bromoimidazo[1,2-a]pyridine Chemical compound C1=C(Br)C=CC2=NC=CN21 FXPMFQUOGYGTAM-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical group NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 2
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MARHZSYEODUGMQ-BDWKERMESA-N C/C=C/C=C/c1c(C)c(-c(cc2)cc3c2OCCO3)ccc1 Chemical compound C/C=C/C=C/c1c(C)c(-c(cc2)cc3c2OCCO3)ccc1 MARHZSYEODUGMQ-BDWKERMESA-N 0.000 description 2
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 239000012270 PD-1 inhibitor Substances 0.000 description 2
- 239000012668 PD-1-inhibitor Substances 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 150000003852 triazoles Chemical group 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- SZYXKFKWFYUOGZ-UHFFFAOYSA-N (2,3-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1F SZYXKFKWFYUOGZ-UHFFFAOYSA-N 0.000 description 1
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
- UJSGZTXLISDWLH-ZEWVGQQJSA-N (2R)-2-[[3-[(E)-2-(2-fluoro-3-phenylphenyl)ethenyl]-4-(trifluoromethyl)phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid Chemical compound FC1=C(C=CC=C1/C=C/C=1C=C(CN[C@@](C(=O)O)(CO)C)C=CC=1C(F)(F)F)C1=CC=CC=C1 UJSGZTXLISDWLH-ZEWVGQQJSA-N 0.000 description 1
- ITARRJJJADSSAW-WUZNFDRSSA-N (2R)-3-hydroxy-2-methyl-2-[[3-[(E)-2-(2-methyl-3-phenylphenyl)ethenyl]-4-(trifluoromethyl)phenyl]methylamino]propanoic acid Chemical compound CC1=C(C=CC=C1/C=C/C=1C=C(CN[C@@](C(=O)O)(CO)C)C=CC=1C(F)(F)F)C1=CC=CC=C1 ITARRJJJADSSAW-WUZNFDRSSA-N 0.000 description 1
- UJSGZTXLISDWLH-CJZRDCOESA-N (2S)-2-[[3-[(E)-2-(2-fluoro-3-phenylphenyl)ethenyl]-4-(trifluoromethyl)phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid Chemical compound FC1=C(C=CC=C1/C=C/C=1C=C(CN[C@](C(=O)O)(CO)C)C=CC=1C(F)(F)F)C1=CC=CC=C1 UJSGZTXLISDWLH-CJZRDCOESA-N 0.000 description 1
- ITARRJJJADSSAW-JYSHFMIGSA-N (2S)-3-hydroxy-2-methyl-2-[[3-[(E)-2-(2-methyl-3-phenylphenyl)ethenyl]-4-(trifluoromethyl)phenyl]methylamino]propanoic acid Chemical compound CC1=C(C=CC=C1/C=C/C=1C=C(CN[C@](C(=O)O)(CO)C)C=CC=1C(F)(F)F)C1=CC=CC=C1 ITARRJJJADSSAW-JYSHFMIGSA-N 0.000 description 1
- UCSNONHSMOQUBH-ITKCEANPSA-N (2S)-3-hydroxy-2-methyl-2-[[3-[(E)-2-[2-methyl-3-(2-methylindazol-6-yl)phenyl]ethenyl]-4-(trifluoromethyl)phenyl]methylamino]propanoic acid Chemical compound OC[C@@](C(=O)O)(NCC1=CC(=C(C=C1)C(F)(F)F)\C=C\C1=C(C(=CC=C1)C=1C=CC2=CN(N=C2C=1)C)C)C UCSNONHSMOQUBH-ITKCEANPSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- IVUHTLFKBDDICS-UHFFFAOYSA-N (4-methylsulfanylphenyl)boronic acid Chemical compound CSC1=CC=C(B(O)O)C=C1 IVUHTLFKBDDICS-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- OCSKCBIGEMSDIS-UHFFFAOYSA-N 1,3-dibromo-2-methylbenzene Chemical compound CC1=C(Br)C=CC=C1Br OCSKCBIGEMSDIS-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- QARVLSVVCXYDNA-RALIUCGRSA-N 1-bromo-2,3,4,5,6-pentadeuteriobenzene Chemical compound [2H]C1=C([2H])C([2H])=C(Br)C([2H])=C1[2H] QARVLSVVCXYDNA-RALIUCGRSA-N 0.000 description 1
- DRNWNTAANHEQMK-UHFFFAOYSA-N 1-bromo-3-chloro-2-fluorobenzene Chemical compound FC1=C(Cl)C=CC=C1Br DRNWNTAANHEQMK-UHFFFAOYSA-N 0.000 description 1
- DMARBQGIQKLIPM-UHFFFAOYSA-N 1-bromo-3-chloro-2-methylbenzene Chemical compound CC1=C(Cl)C=CC=C1Br DMARBQGIQKLIPM-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical group C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
- GBLQHBIRTKNZSR-VAWYXSNFSA-N 2-[1-[3-[(E)-2-(2-methyl-3-phenylphenyl)ethenyl]-4-(trifluoromethyl)phenyl]ethylamino]acetic acid Chemical compound CC1=C(C=CC=C1/C=C/C=1C=C(C=CC=1C(F)(F)F)C(C)NCC(=O)O)C1=CC=CC=C1 GBLQHBIRTKNZSR-VAWYXSNFSA-N 0.000 description 1
- UCHRGTIEJKCDFX-ZHACJKMWSA-N 2-[[3-[(E)-2-[3-(2,3-difluorophenyl)-2-methylphenyl]ethenyl]-4-(trifluoromethyl)phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid Chemical compound FC1=C(C=CC=C1F)C1=C(C(=CC=C1)/C=C/C=1C=C(CNC(C(=O)O)(CO)C)C=CC=1C(F)(F)F)C UCHRGTIEJKCDFX-ZHACJKMWSA-N 0.000 description 1
- ZBOIMINQJATGDJ-MDZDMXLPSA-N 2-[[3-[(E)-2-[3-(2,3-difluorophenyl)-2-methylphenyl]ethenyl]-4-(trifluoromethyl)phenyl]methylamino]-3-hydroxypropanoic acid Chemical compound FC1=C(C=CC=C1F)C1=C(C(=CC=C1)/C=C/C=1C=C(CNC(C(=O)O)CO)C=CC=1C(F)(F)F)C ZBOIMINQJATGDJ-MDZDMXLPSA-N 0.000 description 1
- KUTFKLFMNODILZ-BQYQJAHWSA-N 2-[[3-[(E)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]ethenyl]-4-fluorophenyl]methylamino]-3-hydroxy-2-methylpropanoic acid Chemical compound O1C2=C(OCC1)C=C(C=C2)C=1C(=C(/C=C/C=2C=C(CNC(C(=O)O)(CO)C)C=CC=2F)C=CC=1)C KUTFKLFMNODILZ-BQYQJAHWSA-N 0.000 description 1
- OVBMRCDMPRKCIL-VAWYXSNFSA-N 2-[[3-[(E)-2-[3-(2-fluorophenyl)-2-methylphenyl]ethenyl]-4-(trifluoromethyl)phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid Chemical compound FC1=C(C=CC=C1)C1=C(C(=CC=C1)/C=C/C=1C=C(CNC(C(=O)O)(CO)C)C=CC=1C(F)(F)F)C OVBMRCDMPRKCIL-VAWYXSNFSA-N 0.000 description 1
- WKGNNIQZUDCVJF-ZHACJKMWSA-N 2-[[3-[(E)-2-[3-(3-fluorophenyl)-2-methylphenyl]ethenyl]-4-(trifluoromethyl)phenyl]methylamino]-3-hydroxy-2-methylpropanoic acid Chemical compound FC=1C=C(C=CC=1)C1=C(C(=CC=C1)/C=C/C=1C=C(CNC(C(=O)O)(CO)C)C=CC=1C(F)(F)F)C WKGNNIQZUDCVJF-ZHACJKMWSA-N 0.000 description 1
- YYQRJTFRMKTSDF-UHFFFAOYSA-N 2-[[3-[2-(2-methyl-3-phenylphenyl)ethyl]-4-(trifluoromethyl)phenyl]methylamino]propanoic acid Chemical compound CC1=C(C=CC=C1CCC=1C=C(CNC(C(=O)O)C)C=CC=1C(F)(F)F)C1=CC=CC=C1 YYQRJTFRMKTSDF-UHFFFAOYSA-N 0.000 description 1
- BUIBMFXMAUSPFZ-VOTSOKGWSA-N 2-[[7-[(E)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]ethenyl]-2,3-dihydro-1-benzofuran-5-yl]methylamino]-3-hydroxy-2-methylpropanoic acid Chemical compound O1C2=C(OCC1)C=C(C=C2)C=1C(=C(/C=C/C2=CC(=CC=3CCOC=32)CNC(C(=O)O)(CO)C)C=CC=1)C BUIBMFXMAUSPFZ-VOTSOKGWSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- GELVZYOEQVJIRR-UHFFFAOYSA-N 2-chloropyrazine Chemical compound ClC1=CN=CC=N1 GELVZYOEQVJIRR-UHFFFAOYSA-N 0.000 description 1
- YQKJBPYHCVGERQ-BUHFOSPRSA-N 2-methyl-2-[[3-[(E)-2-(2-methyl-3-phenylphenyl)ethenyl]-4-(trifluoromethyl)phenyl]methylamino]propan-1-ol Chemical compound CC1=C(C=CC=C1/C=C/C=1C=C(CNC(C)(CO)C)C=CC1C(F)(F)F)C1=CC=CC=C1 YQKJBPYHCVGERQ-BUHFOSPRSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- FAHZIKXYYRGSHF-UHFFFAOYSA-N 3-bromo-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1Br FAHZIKXYYRGSHF-UHFFFAOYSA-N 0.000 description 1
- WTXXUAHMTVAQHW-UHFFFAOYSA-N 3-bromo-4-methylbenzaldehyde Chemical compound CC1=CC=C(C=O)C=C1Br WTXXUAHMTVAQHW-UHFFFAOYSA-N 0.000 description 1
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- DXOSJQLIRGXWCF-UHFFFAOYSA-N 3-fluorocatechol Chemical compound OC1=CC=CC(F)=C1O DXOSJQLIRGXWCF-UHFFFAOYSA-N 0.000 description 1
- BUOPAQMETITARQ-VAWYXSNFSA-N 3-hydroxy-2-(hydroxymethyl)-2-[[3-[(E)-2-(2-methyl-3-phenylphenyl)ethenyl]-4-(trifluoromethyl)phenyl]methylamino]propanoic acid Chemical compound CC1=C(C=CC=C1/C=C/C=1C=C(CNC(C(=O)O)(CO)CO)C=CC=1C(F)(F)F)C1=CC=CC=C1 BUOPAQMETITARQ-VAWYXSNFSA-N 0.000 description 1
- WFDFWAGJIJLXCH-CMDGGOBGSA-N 3-hydroxy-2-[[3-[(E)-2-[3-(4-methoxyphenyl)-2-methylphenyl]ethenyl]-4-(trifluoromethyl)phenyl]methylamino]-2-methylpropanoic acid Chemical compound COC1=CC=C(C=C1)C1=C(C(=CC=C1)/C=C/C=1C=C(CNC(C(=O)O)(CO)C)C=CC=1C(F)(F)F)C WFDFWAGJIJLXCH-CMDGGOBGSA-N 0.000 description 1
- WAMGGIKKDDFDIR-UHFFFAOYSA-N 3-hydroxy-2-methyl-2-[[3-[2-(2-methyl-3-phenylphenyl)ethyl]-4-(trifluoromethyl)phenyl]methylamino]propanoic acid Chemical compound CC1=C(C=CC=C1CCC=1C=C(CNC(C(=O)O)(CO)C)C=CC=1C(F)(F)F)C1=CC=CC=C1 WAMGGIKKDDFDIR-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- QHNORIBEFNHZMQ-UHFFFAOYSA-N 6-bromo-1,2-benzoxazole Chemical compound BrC1=CC=C2C=NOC2=C1 QHNORIBEFNHZMQ-UHFFFAOYSA-N 0.000 description 1
- YXVFVHLEIBLKCA-UHFFFAOYSA-N 6-bromo-1,3-benzoxazole Chemical compound BrC1=CC=C2N=COC2=C1 YXVFVHLEIBLKCA-UHFFFAOYSA-N 0.000 description 1
- ZCGXHOLCXPKKBO-UHFFFAOYSA-N 6-bromo-2-methyl-1,3-benzoxazole Chemical compound C1=C(Br)C=C2OC(C)=NC2=C1 ZCGXHOLCXPKKBO-UHFFFAOYSA-N 0.000 description 1
- BVYFYDANLZQCPV-UHFFFAOYSA-N 6-bromo-2-methylindazole Chemical compound C1=CC(Br)=CC2=NN(C)C=C21 BVYFYDANLZQCPV-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000269627 Amphiuma means Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- DUNKRPYOIZHPOZ-MHZLTWQESA-N Bc1c(COCc2cc(OCC(N3CCOCC3)=O)c(CN[C@@H](CO)C(O)=O)cc2C)cccc1-c1ccccc1 Chemical compound Bc1c(COCc2cc(OCC(N3CCOCC3)=O)c(CN[C@@H](CO)C(O)=O)cc2C)cccc1-c1ccccc1 DUNKRPYOIZHPOZ-MHZLTWQESA-N 0.000 description 1
- ALIFTVILOUQAIW-UHFFFAOYSA-N Bc1c(COc2c(C)cc(CN3CCCC3)c(OCC3CC3)c2)cccc1-c(cc1)cc2c1OCCO2 Chemical compound Bc1c(COc2c(C)cc(CN3CCCC3)c(OCC3CC3)c2)cccc1-c(cc1)cc2c1OCCO2 ALIFTVILOUQAIW-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- SZQUZDIHUGRVBD-UHFFFAOYSA-N C(C)(C)C1=C(C(=CC(=C1)C(C)C)C(C)C)C1=CC=CC=C1.C1(CCCCC1)[P] Chemical group C(C)(C)C1=C(C(=CC(=C1)C(C)C)C(C)C)C1=CC=CC=C1.C1(CCCCC1)[P] SZQUZDIHUGRVBD-UHFFFAOYSA-N 0.000 description 1
- SJOGCXVXNFMMJT-YQTDCCHMSA-N C=1(C=CC=C(C=1C)/C=C/C1=C(C=CC(CN[C@H](C(=O)O)CO)=C1)C(F)(F)F)C1=C(F)C=2OCCOC=2C=C1 Chemical compound C=1(C=CC=C(C=1C)/C=C/C1=C(C=CC(CN[C@H](C(=O)O)CO)=C1)C(F)(F)F)C1=C(F)C=2OCCOC=2C=C1 SJOGCXVXNFMMJT-YQTDCCHMSA-N 0.000 description 1
- HEPOIJKOXBKKNJ-UHFFFAOYSA-N CC(C)NCC(O)=O Chemical compound CC(C)NCC(O)=O HEPOIJKOXBKKNJ-UHFFFAOYSA-N 0.000 description 1
- FHJGXYGJKKLYCT-UHFFFAOYSA-N CC(C=CC1F)=CC1Br Chemical compound CC(C=CC1F)=CC1Br FHJGXYGJKKLYCT-UHFFFAOYSA-N 0.000 description 1
- UCHRWFKAVYFZQD-BQYQJAHWSA-N CC12OCCOC1=CC(c1cccc(/C=C/c3c(C(F)(F)F)ccc(CNC(CO)C(O)=O)c3)c1C)=CC2 Chemical compound CC12OCCOC1=CC(c1cccc(/C=C/c3c(C(F)(F)F)ccc(CNC(CO)C(O)=O)c3)c1C)=CC2 UCHRWFKAVYFZQD-BQYQJAHWSA-N 0.000 description 1
- IVKQKJFBMNPJLF-OZSKJFCKSA-N C[C@@H](C(O)=O)NCc1cc(/C=C/c2c(C)c(-c(ccc3c4OCCO3)c4F)ccc2)c(C(F)(F)F)cc1 Chemical compound C[C@@H](C(O)=O)NCc1cc(/C=C/c2c(C)c(-c(ccc3c4OCCO3)c4F)ccc2)c(C(F)(F)F)cc1 IVKQKJFBMNPJLF-OZSKJFCKSA-N 0.000 description 1
- HIEFKIHIZFKWGJ-UHFFFAOYSA-N C[n]1c(C(Nc2cccc(-c3c(cn[n]4C)c4ccc3)c2C#N)=O)ncc1CNCCO Chemical compound C[n]1c(C(Nc2cccc(-c3c(cn[n]4C)c4ccc3)c2C#N)=O)ncc1CNCCO HIEFKIHIZFKWGJ-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZNOWLLPAHTWELC-UHFFFAOYSA-N Cc(c(-c1ccccc1)ccc1)c1-c1nc(cc(CNCCO)cc2)c2[o]1 Chemical compound Cc(c(-c1ccccc1)ccc1)c1-c1nc(cc(CNCCO)cc2)c2[o]1 ZNOWLLPAHTWELC-UHFFFAOYSA-N 0.000 description 1
- VOAPZIOYQDRHOO-UHFFFAOYSA-N Cc(c(NC(c1n[n](C)c(CNCCO)c1)=O)ccc1)c1-c1ccccc1 Chemical compound Cc(c(NC(c1n[n](C)c(CNCCO)c1)=O)ccc1)c1-c1ccccc1 VOAPZIOYQDRHOO-UHFFFAOYSA-N 0.000 description 1
- ZYVCLVFNLKSHAF-CMDGGOBGSA-N Cc1c(/C=C/c2c(C)c(-c(ccc3c4OCCO3)c4F)ccc2)cc(CNC(CO)C(O)=O)cc1 Chemical compound Cc1c(/C=C/c2c(C)c(-c(ccc3c4OCCO3)c4F)ccc2)cc(CNC(CO)C(O)=O)cc1 ZYVCLVFNLKSHAF-CMDGGOBGSA-N 0.000 description 1
- BSWGZCMLNFBDEZ-UHFFFAOYSA-N Cc1c(C)[o]nc1 Chemical compound Cc1c(C)[o]nc1 BSWGZCMLNFBDEZ-UHFFFAOYSA-N 0.000 description 1
- VQTVFIMEENGCJA-UHFFFAOYSA-N Cc1c[nH]nc1C Chemical compound Cc1c[nH]nc1C VQTVFIMEENGCJA-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- QUENZSUNKWDVEL-BQYQJAHWSA-N FC1=C(C=CC=2OCCOC=21)C=1C(=C(/C=C/C=2C=C(CNC(C(=O)O)(CO)C)C=CC=2C(F)(F)F)C=CC=1)C Chemical compound FC1=C(C=CC=2OCCOC=21)C=1C(=C(/C=C/C=2C=C(CNC(C(=O)O)(CO)C)C=CC=2C(F)(F)F)C=CC=1)C QUENZSUNKWDVEL-BQYQJAHWSA-N 0.000 description 1
- ZYVCLVFNLKSHAF-KDLSMAQYSA-N FC1=C(C=CC=2OCCOC=21)C=1C(=C(/C=C/C=2C=C(CN[C@H](C(=O)O)CO)C=CC=2C)C=CC=1)C Chemical compound FC1=C(C=CC=2OCCOC=21)C=1C(=C(/C=C/C=2C=C(CN[C@H](C(=O)O)CO)C=CC=2C)C=CC=1)C ZYVCLVFNLKSHAF-KDLSMAQYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- WQANFSIOHREVIV-VOTSOKGWSA-N O1C2=C(OCC1)C=C(C=C2)C=1C(=C(/C=C/C=2C=C(CNC(C(=O)O)CO)C=CC=2F)C=CC=1)C Chemical compound O1C2=C(OCC1)C=C(C=C2)C=1C(=C(/C=C/C=2C=C(CNC(C(=O)O)CO)C=CC=2F)C=CC=1)C WQANFSIOHREVIV-VOTSOKGWSA-N 0.000 description 1
- YEOHHQAXGGADFI-UHFFFAOYSA-N OB(O)OC=C.CC(C)(O)C(C)(C)O Chemical compound OB(O)OC=C.CC(C)(O)C(C)(C)O YEOHHQAXGGADFI-UHFFFAOYSA-N 0.000 description 1
- AKBUZVMIUGEQNL-UROCCOEBSA-N OC[C@@](C(=O)O)(NCC1=CC(=C(C=C1)C(F)(F)F)\C=C\C1=C(C(=CC=C1)C1=NC=CN=C1)C)C Chemical compound OC[C@@](C(=O)O)(NCC1=CC(=C(C=C1)C(F)(F)F)\C=C\C1=C(C(=CC=C1)C1=NC=CN=C1)C)C AKBUZVMIUGEQNL-UROCCOEBSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920001304 Solutol HS 15 Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ITARRJJJADSSAW-OXDVIYIQSA-N [2H]C1=C(C(=C(C(=C1[2H])[2H])C2=CC=CC(=C2C)/C=C/C3=C(C=CC(=C3)CN[C@@](C)(CO)C(=O)O)C(F)(F)F)[2H])[2H] Chemical compound [2H]C1=C(C(=C(C(=C1[2H])[2H])C2=CC=CC(=C2C)/C=C/C3=C(C=CC(=C3)CN[C@@](C)(CO)C(=O)O)C(F)(F)F)[2H])[2H] ITARRJJJADSSAW-OXDVIYIQSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QGZKDVFQNNGYKY-NJFSPNSNSA-N nitrogen-16 Chemical compound [16NH3] QGZKDVFQNNGYKY-NJFSPNSNSA-N 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940097886 phosphorus 32 Drugs 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- RLJWTAURUFQFJP-UHFFFAOYSA-N propan-2-ol;titanium Chemical compound [Ti].CC(C)O.CC(C)O.CC(C)O.CC(C)O RLJWTAURUFQFJP-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- CESUXLKAADQNTB-UHFFFAOYSA-N tert-butanesulfinamide Chemical compound CC(C)(C)S(N)=O CESUXLKAADQNTB-UHFFFAOYSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N tetraisopropyl titanate Substances CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present invention relates to a small molecule PD-1/PD-L1 inhibitor, a pharmaceutical composition thereof and PD-L1 antibody, and applications thereof.
- Human programmed death factor ligand 1 (PD-L1), also known as B7-H1, belongs to the B7 family and is widely distributed in peripheral tissues and hematopoietic cells.
- PD-L1q full-length cDNA 870bp, encoding a type I transmembrane protein containing 290 amino acids, PD-L1 is mainly expressed in the bearing CD4 T cells, CD8 T cells, B cells, monocytes, and dendritic cells (Dendritic Cells, DCs), macrophages and other hematopoietic cells and some non-hematopoietic cells, such as endothelial cells, pancreatic islet cells, mast cells and other membrane surfaces.
- PD-L1 is highly expressed in a variety of tumors, such as lung cancer, gastric cancer, multiple bone marrow, melanoma and breast cancer.
- Programmed death-1 (PD-1) is the main receptor of PD-L1. It is mainly distributed in immune-related cells such as T cells, B cells and NK cells. It is used in autoimmune diseases, tumors, infections, and organs. Transplantation, allergies, immune privileges, etc. all play an important role in the immune response process.
- PD-L1 inhibits the activation of T cells or induces apoptosis of mature T cells by interacting with its receptor programmed death factor 1, so that the immune response is inhibited.
- cancer cells will up-regulate the expression of PD-L1 to induce apoptosis of T cells and prevent the immune system from eliminating them.
- PD-L1 targeting antibody drugs can break the tumor immune tolerance by specifically blocking the interaction of PD-1/PD-L1, restore the killing function of tumor-specific T cells to tumor cells, and then achieve tumor clearance.
- the indications include melanoma, urothelial cancer (bladder cancer), and metastatic non-small cell Lung cancer (stage IV); AstraZeneca's Durvalumab (devaruzumab, trade name: Imfinzi), indicated for advanced or metastatic urothelial cancer (bladder cancer); Pfizer and Merck's Avelumab (trade name) : Bavencio), the indication is rare skin cancer Merck cell carcinoma (MCC); Regeneron’s Cemiplimab (trade name: Libtayo), the indication is the treatment of metastatic or locally advanced skin squamous cell carcinoma.
- MCC Merck cell carcinoma
- Regeneron’s Cemiplimab trade name: Libtayo
- PD-L1 antibody drugs under development, such as the PD-L1 antibody developed by companies such as Corning Jereh, CStone Pharmaceuticals, Hengrui Pharmaceuticals, Maibos, BeiGene, Kelun Botai and Zhaoke Pharmaceuticals.
- the drug has already started clinical research.
- Atezolizumab By analyzing the crystal complex of Atezolizumab, the first PD-L1 antibody approved for marketing by the FDA (Oncotarget, 2017, 8, 90215-90224), it can be found that the combination of Atezolizumab and PD-L1 involves a large number of hydrogen bonds, hydrophobic Interaction and ⁇ - ⁇ superposition or cation- ⁇ interaction. In addition, mutation studies have shown that PD-L1 has two hot residues (E58, R113). In conclusion, Atezolizumab competes with PD-1 for the same surface binding site of PD-L1.
- WO2018006795 discloses a new small molecule PD-1/PD-L1 inhibitor that has shown anti-tumor effects in mouse tumor models.
- the technical problem to be solved by the present invention is to provide a small molecule PD-1/PD-L1 inhibitor, a pharmaceutical composition with PD-L1 antibody, and application thereof.
- the present invention provides an aromatic vinyl or aromatic ethyl derivative represented by the general formula (I), its pharmaceutically acceptable salt, deuterated product, metabolite, metabolic precursor or prodrug:
- Each R 1 is the same or different, and is each independently deuterium, halogen, substituted or unsubstituted hydroxy, substituted or unsubstituted amino, substituted or unsubstituted alkyl, or substituted or unsubstituted alkoxy;
- R 2 is substituted or unsubstituted alkyl or halogen
- Each R 3 is the same or different and is each independently deuterium, halogen, substituted or unsubstituted alkylthio, substituted or unsubstituted hydroxyl, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted Substituted alkoxy,
- R 1a is a C 1 -C 4 alkyl group, or two adjacent R 3 and the two carbon atoms connected to them together form a 5-7 membered carbocyclic or carbocyclic ring; the carbocyclic ring Where the heteroatoms are oxygen and/or nitrogen, and the number of heteroatoms is 1-4;
- the substituent in the substituted alkyl group, the substituted alkoxy group or the substituted alkylthio group is selected from one or more of the following groups One: halogen, C 1-4 alkyl, hydroxyl, A C 1-4 alkoxy group, a carboxy C 1-4, C 1-4 and C 1-4 ester group an amide group; when a plurality of substituents, the substituents are the same or different;
- R a and R b are independently hydrogen, or a substituted or unsubstituted alkyl group;
- R a or R b the substituted alkyl group in a substituent selected from the group of one or more of: halo, C 1 -C 4 alkyl, hydroxyl, C 1 -C 4 alkoxy group, C 1 -C 4 carboxyl group, C 1 -C 4 ester group or C 1 -C 4 amide group;
- R a1 and R b1 are independently hydrogen or C 1 -C 4
- the substituent in the substituted hydroxy group or the substituted amino group is selected from one or more of the following groups: C 1-4 alkyl, C 1 -4 alkoxy group, C 1-4 carboxyl group, C 1-4 ester group and C 1-4 amide group;
- n 1, 2, 3, 4 or 5, preferably 1, 2 or 3;
- n 0, 1, 2, 3, 4 or 5, preferably 0, 1, 2 or 3;
- aromatic vinyl or aromatic ethyl derivatives represented by the general formula (I) are not the following compounds:
- each R 1 is independently halogen, or, substituted or unsubstituted alkyl; or two adjacent R 1 and two carbon atoms connected to it together form a 5-7 Membered carbon heterocycle.
- each R 1 is independently halogen, substituted or unsubstituted alkyl, or substituted or unsubstituted alkoxy.
- R 2 is alkyl or halogen.
- each R 3 is independently halogen, alkylthio or alkoxy; or two adjacent R 3 and the two carbon atoms connected to them together form a 5-7 member ⁇ carbon heterocycle.
- the substituent in the substituted alkyl group is selected from one or more of the following groups: halogen or R a and R b are independently hydrogen, or a substituted or unsubstituted alkyl group; R a or R b, the substituted alkyl group in a substituent selected from the group of one or more of: Hydroxyl group or C 1 -C 4 carboxyl group.
- the substituent in the substituted alkyl group, the substituted alkoxy group, the substituted hydroxy group or the substituted amino group means a Or more halogen substitutions, preferably one or more F substitutions.
- the two adjacent R 3 and the two carbon atoms connected to them together form a 5-7 membered carbocyclic ring or carbocyclic ring
- the carbocyclic or carbocyclic heterocyclic ring may be further substituted by one or more of C 1-4 alkyl (e.g. ).
- heteroatoms in the heteroaromatic ring are selected from N, O and S, and the number of heteroatoms is 1-4.
- the substituents are selected from one or more of the following groups: halogen, C 1-4 alkyl, hydroxyl, A C 1-4 alkoxy group, a carboxy C 1-4, C 1-4 and C 1-4 ester group an amide group; when a plurality of substituents, the substituents are the same or different; R a and R b are independently hydrogen, or a substituted or unsubstituted alkyl group; R a or R b, the substituted alkyl group in a substituent selected from the group of one or more of: halo, C 1 -C 4 alkyl, hydroxyl, C 1 -C 4 alkoxy group, C 1 -C 4 carboxyl group, C 1 -C 4 ester group or C 1 -C 4 amide group; R a1 and R b1 are independently hydrogen or C 1 -C 4 alkyl ;
- the substituents in the substituted heteroaromatic ring are preferably one or more
- the heteroatoms in the heteroaromatic ring are selected from N and O, and the number of heteroatoms is 1-3.
- the heteroatom is a N atom and the number of heteroatoms is 1 or 2; when the heteroaromatic ring is a bicyclic heteroaryl group and the heteroatom is N, the number of heteroatoms is preferably 3;
- the heteroaromatic ring is a bicyclic heteroaryl, the heteroatom is selected from N and O, and the number of heteroatoms is 2; the heteroatoms are not adjacent.
- n is 0, 1, 2, 3, 4 or 5, preferably 0, 1, 2 or 3.
- R 3 is preferably halogen, alkylthio or alkoxy; and R 3 is located at the ortho, meta or para position of the benzene ring, for example
- n is 2, preferably, two R 3 are located at the ortho and meta positions of the benzene ring, for example Wherein, two R 3 are the same or different; or two R 3 are adjacent, and two adjacent R 3 and the two carbon atoms connected to them together form a 5-7 membered carbocyclic ring, for example
- the ring M is a 5-7 membered carbocyclic ring.
- Ring M is a 5-7 membered carbocyclic ring (e.g. 2,3-dihydro-1,4-dioxane Oxazole ring such as Isoxazole ring such as Pyrazole ring such as ); Ring M may be further substituted by one or more of C 1-4 alkyl groups (for example ).
- n is 4 or 5, preferably R 3 is deuterium;
- m is 2 or 3.
- the two R 1 are preferably located at the ortho and meta positions of the benzene ring, for example The two R 1 are the same or different.
- m is 3, preferably, two R 1 are adjacent, and the two adjacent R 1 and the two carbon atoms connected to them together form a 5-7 membered carbocyclic ring, for example Wherein Ring N is a 5-7 membered carbocyclic ring, such as 2,3-dihydrofuran ring
- two R 1 are located at the ortho and meta positions of the benzene ring respectively, and the two R 1 are the same or different; the R 1 at the ortho position of the benzene ring is F, A substituted or unsubstituted alkyl group, or a substituted or unsubstituted alkoxy group.
- one of R 1 (preferably located at the ortho position of the benzene ring) is preferably an alkyl or halogen-substituted alkyl; the other R 1 (preferably located at the meta position of the benzene ring) is preferably Substituted alkyl; when m is 3, two R 1 are adjacent, and the two adjacent R 1 and the two carbon atoms connected to them together form a 5-7 membered carbocyclic ring, the third R 1 is Substituted alkyl; wherein, the alkyl group is preferably a C 1-4 alkyl group.
- the halogen-substituted alkyl group is preferably a C 1 -C 4 alkyl group substituted by one or more halogens, such as trifluoromethyl. Said The substituted alkyl group is preferably Substituted C 1 -C 4 alkyl.
- the The substituted C 1 -C 4 alkyl group is preferably Wherein, R a and R b are one of H, the other is substituted with a hydroxyl group and / or carboxyalkyl.
- the The substituted C 1 -C 4 alkyl group is preferably Among them, the carbons marked with * are S-configuration chiral carbons, R-configuration chiral carbons or achiral carbons. among them, Preferably Preferably Preferably Preferably Preferably Preferably Preferably Preferably Preferably
- Each R 1 is independently halogen, or, substituted or unsubstituted alkyl; or two adjacent R 1 and two carbon atoms connected to it together form a 5-7 membered carbocyclic ring;
- R 2 is alkyl or halogen
- Each R 3 is independently deuterium, halogen, alkylthio or alkoxy; or two adjacent R 3 and the two carbon atoms connected to them together form a 5-7 membered carbocyclic ring;
- n 0, 1, 2, 3, 4 or 5, preferably 0, 1, 2 or 3;
- Each R 1 is independently deuterium, or, substituted or unsubstituted alkyl; or two adjacent R 1 and two carbon atoms connected to it together form a 5-7 membered carbocyclic ring;
- the substituent in the substituted alkyl group is selected from one or more of the following groups: halogen or R a and R b are independently hydrogen, or a substituted or unsubstituted alkyl group; R a or R b, the substituted alkyl group in a substituent selected from the group of one or more of: Hydroxyl group or C 1 -C 4 carboxyl group;
- R 2 is alkyl or halogen
- Each R 3 is independently deuterium, halogen, alkylthio or alkoxy; or two adjacent R 3 and the two carbon atoms connected to them together form a 5-7 membered carbocyclic ring;
- n 0, 1, 2, 3, 4 or 5, preferably 0, 1, 2 or 3.
- R 3 is preferably halogen, alkylthio or alkoxy; and R 3 is located on the benzene ring Ortho, meta, or para, for example
- n 2 preferably, two R 3 are located at the ortho and meta positions of the benzene ring, for example Wherein, two R 3 are the same or different; or two R 3 are adjacent, and two adjacent R 3 and the two carbon atoms connected to them together form a 5-7 membered carbocyclic ring; for example Wherein ring M is a 5- to 7-membered carbocyclic ring; when n is 3, preferably, one of R 3 is halogen, the other two R 3 are adjacent, and the adjacent two R 3 are connected to them Two carbon atoms together form a 5-7 membered carbocyclic ring, for example Wherein ring M is a 5-7 membered carbocyclic ring;
- m are 2 or 3; when m is 2, two R 1 are preferably located at the ortho and meta positions of the benzene ring, for example R 1 located at the ortho position of the benzene ring is preferably an alkyl group or halogen substituted alkyl; R 1 located at the meta position of the benzene ring is preferably Substituted alkyl; when m is 3, two R 1 are adjacent, and the two adjacent R 1 and the two carbon atoms connected to them together form a 5-7 membered carbocyclic ring, the third R 1 is Substituted alkyl; when n is 4 or 5, R 3 is deuterium.
- Each R 1 is independently halogen, substituted or unsubstituted alkyl, or substituted or unsubstituted alkoxy;
- R 2 is substituted or unsubstituted alkyl or halogen
- Each R 3 is independently deuterium, halogen, substituted or unsubstituted alkylthio, substituted or unsubstituted hydroxy, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy ,
- R 1a is a C 1 -C 4 alkyl group
- the substituent in the substituted alkyl group, the substituted alkoxy group, the substituted hydroxy group or the substituted amino group refers to substitution by one or more halogens, Preferably substituted by one or more F;
- the substituents in the substituted alkyl group described in each R 2 and each R 3 , the substituted alkoxy group described in each R 3 and the substituted alkylthio group are selected from the following groups One or more of: halogen, C 1-4 alkyl, hydroxyl, A C 1-4 alkoxy group, a carboxy C 1-4, C 1-4 and C 1-4 ester group an amide group; when a plurality of substituents, the substituents are the same or different; R a and R b are independently hydrogen, or a substituted or unsubstituted alkyl group; R a or R b, the substituted alkyl group in a substituent selected from the group of one or more of: halo, C 1 -C 4 alkyl, hydroxyl, C 1 -C 4 alkoxy group, C 1 -C 4 carboxyl group, C 1 -C 4 ester group or C 1 -C 4 amide group; R a1 and R b1 are independently hydrogen or
- the substituent in the substituted hydroxy group or the substituted amino group is selected from one or more of the following groups: C 1-4 alkyl, C 1-4 alkoxy Group, C 1-4 carboxyl group, C 1-4 ester group and C 1-4 amide group;
- n 2 or 3;
- n 0, 1, 2, 3, 4 or 5, preferably 0, 1, 2 or 3;
- R 1 When m is 2, two R 1 each located at the benzene ring ortho and meta positions, the same or different two R < located on the benzene ring ortho position, R 1 is F, a substituted or unsubstituted alkyl group, or Substituted or unsubstituted alkoxy;
- the heteroatoms in the heteroaromatic ring are selected from N, O and S, and the number of heteroatoms is 1-4;
- the substituents in the substituted heteroaromatic ring One or more selected from the following groups: halogen, C 1-4 alkyl, hydroxyl, A C 1-4 alkoxy group, a carboxy C 1-4, C 1-4 and C 1-4 ester group an amide group; when a plurality of substituents, the substituents are the same or different;
- R a and R b are independently hydrogen, or a substituted or unsubstituted alkyl group;
- R a or R b the substituted alkyl group in a substituent selected from the group of one or more of: halo, C 1 -C 4 alkyl, hydroxyl, C 1 -C 4 alkoxy group, C 1
- R 3 is halogen or alkoxy, and R 3 is located at the para position of the benzene ring, m is 2 or 3, and when m is 2, it is located at the ortho position of the benzene ring.
- R 1 is preferably a halogen-substituted alkyl group.
- R 3 when n is 1 and R 3 is halogen, R 3 is preferably F or Cl. When R 3 is F, R 3 is preferably in the meta position of the benzene ring.
- R 3 is deuterium
- aromatic vinyl or aromatic ethyl derivatives represented by the general formula (I) are preferably any of the following compounds:
- aromatic vinyl or aromatic ethyl derivatives represented by general formula (I) are preferably aromatic vinyl or aromatic ethyl derivatives represented by general formula (II):
- R 1, R 2, R 3, n, R a R b are as previously defined and the.
- the present invention also provides a preparation method of the aromatic vinyl or aromatic ethyl derivatives represented by the general formula (II), which comprises the following steps: combining compound (Ia) with Carry out the reductive amination reaction shown below to obtain the compound represented by the general formula (II);
- R 1, R 2, R 3, n, R a R b are defined as previously described and, M1 is 2, 3 or 4, preferably 0, 1 or 2.
- the method and conditions of the reductive amination reaction can be conventional methods and conditions of such reactions in the art.
- the acid may also be added to the reductive amination reaction.
- the acid is preferably an inorganic acid and/or an organic acid.
- the inorganic acid is preferably hydrochloric acid and/or sulfuric acid.
- the organic acid is preferably glacial acetic acid.
- the molar ratio of the acid to the compound (I-a) is preferably 0.2:1 to 5:1 (for example, 2:1).
- the solvent is preferably an organic solvent and/or water.
- the organic solvent may be an organic solvent commonly used in such reactions in the art, preferably one or more of alcohol solvents, chlorinated hydrocarbon solvents, ether solvents and amide solvents.
- the alcohol solvent is preferably methanol and/or ethanol.
- the halogenated hydrocarbon solvent is preferably dichloromethane.
- the ether solvent is preferably 1,4-dioxane.
- the amide solvent is preferably N,N-dimethylformamide.
- the solvent is preferably a mixed solvent of alcohol solvent and chlorinated hydrocarbon solvent, such as a mixed solvent of methanol and dichloromethane.
- the volume ratio of the alcohol solvent to the chlorinated hydrocarbon solvent is preferably 1:0.1 to 1:5 (for example, 1:1).
- the amount of the solvent may not be specifically limited as long as it does not affect the progress of the reaction.
- the volume-to-mass ratio of the solvent to the compound represented by compound (I-a) is preferably 10 mL/g-200 mL/g.
- the reducing agent may be a reducing agent commonly used in such reductive amination reactions, preferably one or more of sodium cyanoborohydride, sodium acetate borohydride, sodium borohydride and lithium borohydride, preferably cyanoborohydride sodium.
- the molar ratio of the reducing agent to the compound (I-a) is preferably 0.3:1 to 10:1 (for example, 5:1).
- compound (Ia) and The molar ratio of is preferably 1:1-1:3 (preferably 1:2).
- the temperature of the reductive amination reaction is preferably 0°C to 120°C, more preferably 0°C to 50°C, and further preferably room temperature (10°C to 30°C).
- the progress of the reductive amination reaction can be monitored by TLC or HPLC, and the end of the reaction is generally when the compound (I-a) disappears.
- the product can be further purified by post-treatment.
- the method for preparing the compound (Ia) preferably includes the following steps: in a solvent, under the action of a palladium catalyst, compound (II-b) and Carry out the coupling reaction shown below to obtain compound (Ia), and that is;
- R 1, R 2, R 3, n, R a R b are defined as previously described and, X is halogen, M1 is 2, 3 or 4, preferably 0, 1 or 2.
- the methods and conditions of the coupling reaction can be conventional methods and conditions of such reactions in the art.
- a base may be added to the coupling reaction.
- the base is preferably an alkali metal carbonate, more preferably sodium carbonate, potassium carbonate or cesium carbonate.
- the molar ratio of the base to the compound (II-b) is preferably 1:1-5:1.
- the solvent is preferably an organic solvent and/or water.
- the organic solvent may be an organic solvent commonly used in such reactions in the field, preferably one or more of ether solvents, aromatic hydrocarbon solvents and amide solvents.
- the ether solvents are preferably 1,4-dioxane and ethylene glycol dimethyl ether.
- the aromatic hydrocarbon solvent is preferably toluene.
- the amide solvent is preferably N,N-dimethylformamide.
- the solvent is preferably aromatic hydrocarbon solvent.
- the volume mass ratio of the solvent to the compound (II-b) is preferably 10 mL/g to 110 mL/g.
- the palladium catalyst may be a palladium catalyst commonly used in such coupling reactions, preferably [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride, One or more of tris(dibenzylidene indeneacetone) dipalladium, palladium acetate, and tetrakis(triphenylphosphine)palladium.
- the molar ratio of the palladium catalyst to the compound (II-b) is preferably 0.005:1 to 0.5:1, more preferably 0.01:1 to 0.10:1.
- the coupling reaction is preferably carried out under the action of a ligand, and the ligand is preferably 2-dicyclohexylphosphorus-2',4',6'-triisopropyl Biphenyl.
- the temperature of the coupling reaction is preferably 50°C to 150°C (for example, 80 to 90°C).
- the progress of the coupling reaction can be monitored by TLC or HPLC, and the end of the reaction is generally when compound (II-b) disappears.
- the product can be further purified by post-treatment.
- the compound of the present invention can be obtained by a variety of methods well known in the art and using known raw materials, such as chemical synthesis or extraction from plants. These methods are all included in the present invention. Unless otherwise specified or a preparation method is provided, the raw materials used to prepare the compound of the present invention or its intermediates are all known in the art or commercially available.
- the present invention also provides the aromatic vinyl or aromatic ethyl derivatives represented by the general formula (I), pharmaceutically acceptable salts, deuterated substances, metabolites, metabolic precursors or prodrugs used in the preparation of PD -1 inhibitors and/or PD-L1 inhibitors.
- the present invention also provides the aromatic vinyl or aromatic ethyl derivatives represented by the general formula (I), its pharmaceutically acceptable salts, deuterated products, metabolites, metabolic precursors or prodrugs used in the preparation Application in drugs for preventing, relieving or treating cancer, infection, autoimmune disease or related diseases.
- the aromatic vinyl or aromatic ethyl derivatives represented by the general formula (I) its pharmaceutically acceptable salts, deuterated products, metabolites, metabolic precursors or prodrugs used in the preparation Application in drugs for preventing, relieving or treating cancer, infection, autoimmune disease or related diseases.
- the cancer is preferably one or more of lung cancer, esophageal cancer, gastric cancer, colorectal cancer, liver cancer, nasopharyngeal cancer, brain tumor, breast cancer, cervical cancer, blood cancer and bone cancer.
- the present invention also provides a pharmaceutical composition, which comprises a therapeutically and/or preventively effective amount of the aromatic vinyl or aromatic ethyl derivative represented by the general formula (I), its pharmaceutically acceptable salt, Deuterated products, metabolites, metabolic precursors or prodrugs, and pharmaceutically acceptable carriers and/or diluents.
- a pharmaceutical composition which comprises a therapeutically and/or preventively effective amount of the aromatic vinyl or aromatic ethyl derivative represented by the general formula (I), its pharmaceutically acceptable salt, Deuterated products, metabolites, metabolic precursors or prodrugs, and pharmaceutically acceptable carriers and/or diluents.
- the present invention also provides a pharmaceutical composition, which comprises:
- the PD-L1 antibody may be one or more of Atezolizumab (atezolizumab), Durvalumab, Avelumab, Cemiplimab, KN035, CS1001, MBS2311, BGB-A333, KL-A167, SHR-1316 and STI-A1014 Kind.
- the PD-L1 antibody is Durvalumab.
- the small molecule PD-1/PD-L1 inhibitor is an aromatic vinyl or aromatic ethyl derivative, a pharmaceutically acceptable salt, deuterated product, metabolite, metabolic precursor, or prodrug body.
- the molecular weight of the small molecule PD-1/PD-L1 inhibitor is less than 1500 daltons, for example, less than 1400, 1300, 1200, 1100, 1000, 900, 800, 700, 600 or 500 daltons pause.
- the small molecule PD-1/PD-L1 inhibitor has a PD-1/PD-L1 binding experiment (for example, the PD-1/PD-L1 binding experiment in Effect Example 1 herein) IC 50 values of less than 100nM, for example less than 90nM, 80nM, 70nM, 60nM, 50nM, 40nM, 30nM, 20nM, IC 50 values of 10nM or 1nM.
- the small molecule PD-1/PD-L1 inhibitor binds to PD-L1. In some embodiments, the small molecule PD-1/PD-L1 inhibitor binds to PD-1.
- the small molecule PD-1/PD-L1 inhibitor is a PD-L1 inhibitor. In some embodiments, the small molecule PD-1/PD-L1 inhibitor is a PD-1 inhibitor.
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention include compounds disclosed in WO2015034820 (the entirety of which is incorporated herein by reference), such as
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2018009505 (the entirety of which is incorporated herein by reference), such as
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2018195321 (the entirety of which is incorporated herein by reference), for example
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2018119263 (the entirety of which is incorporated herein by reference), such as
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2018119221 (the entirety of which is incorporated herein by reference), such as
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2018119224 (the entirety of which is incorporated herein by reference), for example
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2018119236 (the entirety of which is incorporated herein by reference), for example
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2018119266 (the entirety of which is incorporated herein by reference), for example
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2018119286 (the entirety of which is incorporated herein by reference), such as
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include the compounds disclosed in WO2018044783 (the entirety of which is incorporated herein by reference), such as
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2018013789 (the entirety of which is incorporated herein by reference), for example
- the small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2017222976 (the entirety of which is incorporated herein by reference), such as
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2017205464 (the entirety of which is incorporated herein by reference), for example
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2017192961 (the entirety of which is incorporated herein by reference), for example
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2017112730 (the entirety of which is incorporated herein by reference), for example
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2017106634 (the entirety of which is incorporated herein by reference), for example
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2017087777 (the entirety of which is incorporated herein by reference), for example
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2017070089 (the entirety of which is incorporated herein by reference), such as
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2018026971 (the entirety of which is incorporated herein by reference), for example
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2018005374 (the entirety of which is incorporated herein by reference), for example
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2018051254 (the entirety of which is incorporated herein by reference), for example
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds described in CN201711445262.9 (the full text of which is incorporated herein by reference), for example
- the small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds described in CN201710064453.4 (the full text of which is incorporated herein by reference), for example
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2017202273 (the entirety of which is incorporated herein by reference), such as
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2017202275 (the entirety of which is incorporated herein by reference), for example
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in WO2017202276 (the entirety of which is incorporated herein by reference), for example
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include the compounds disclosed in WO2018006795 (the entirety of which is incorporated herein by reference).
- Small molecule PD-1/PD-L1 inhibitors within the scope of the present invention also include compounds disclosed in CN201710539028.6 (the entirety of which is incorporated herein by reference), for example
- the small molecule PD-1/PD-L1 inhibitor can also be an aromatic vinyl or aromatic ethyl derivative represented by the general formula (I) as described above, and its pharmaceutically acceptable Salt, deuterium, metabolite, metabolic precursor or prodrug.
- the small molecule PD-1/PD-L1 inhibitor is compound 29 or a pharmaceutically acceptable salt thereof.
- the PD-L1 antibody is Durvalumab
- the small molecule PD-1/PD-L1 inhibitor is compound 29 Or a pharmaceutically acceptable salt thereof.
- the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor may be present in a single pharmaceutical composition, or may be present in separate separate pharmaceutical compositions.
- PD-L1 antibody and small molecule PD-1/PD-L1 inhibitor need to be administered by different routes of administration or different dosing intervals, PD-L1 antibody and small molecule PD-1/PD-L1 inhibition are preferred
- the agents are present in separate separate pharmaceutical compositions.
- the pharmaceutical composition may also include a pharmaceutically acceptable carrier.
- the pharmaceutical composition comprises:
- a pharmaceutically acceptable carrier is selected from:
- the pharmaceutical composition comprises:
- the first pharmaceutical composition which comprises a PD-L1 antibody and a pharmaceutically acceptable carrier;
- the second pharmaceutical composition comprises a small molecule PD-1/PD-L1 inhibitor or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- the pharmaceutical composition can be made into various suitable dosage forms according to different administration modes, including dosage forms for gastrointestinal administration (for example, oral dosage forms) and parenteral administration forms (for example, injection dosage forms).
- the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor can be in a single unit dosage form, or they can be in different unit dosage forms.
- the route and interval of administration of PD-L1 antibody and small molecule PD-1/PD-L1 inhibitor are different, it is preferable that PD-L1 antibody and small molecule PD-1/PD-L1 inhibitor exist in different units In the dosage form.
- the PD-L1 antibody is in an injection dosage form, such as a subcutaneous injection dosage form, an intramuscular injection dosage form, or an intravenous injection dosage form.
- the PD-L1 antibody is in the form of subcutaneous injection.
- the PD-L1 antibody is in an intravenous dosage form.
- the PD-L1 antibody is Durvalumab, which is in the form of injection.
- the PD-L1 antibody is Durvalumab, which is in the form of subcutaneous injection.
- the PD-L1 antibody is Durvalumab, which is an intravenous injection formulation.
- the small molecule PD-1/PD-L1 inhibitor is an oral dosage form, such as an oral solid dosage form (e.g., tablet, capsule, pill, granule) and an oral liquid dosage form (e.g., oral solution, Oral suspension or syrup).
- an oral solid dosage form e.g., tablet, capsule, pill, granule
- an oral liquid dosage form e.g., oral solution, Oral suspension or syrup
- the small molecule PD-1/PD-L1 inhibitor is an oral liquid dosage form, such as an oral suspension.
- the small molecule PD-1/PD-L1 inhibitor is compound 29, which is an oral liquid dosage form, such as an oral suspension.
- the small molecule PD-1/PD-L1 inhibitor is compound 29, which is 10% (w/v) polyoxyethylene hydrogenated castor oil 40 (Cremophor RH40), 20% (w/v) ) Sulfobutyl ether- ⁇ -cyclodextrin (SBE- ⁇ -CD) and 70% (w/v) water of compound 29 suspension (that is, a certain amount of compound 29 is suspended in 10% (w/v) ) Polyoxyethylene hydrogenated castor oil 40, 20% sulfobutyl ether- ⁇ -cyclodextrin and 70% water in a mixed solution).
- the PD-L1 antibody is Durvalumab
- the small molecule PD-1/PD-L1 inhibitor is compound 29 or a pharmaceutically acceptable salt thereof
- Durvalumab is an injection dosage form
- Compound 29 is an oral dosage form.
- the PD-L1 antibody is Durvalumab
- the small molecule PD-1/PD-L1 inhibitor is compound 29 or a pharmaceutically acceptable salt thereof
- Durvalumab is a subcutaneous injection dosage form
- Compound 29 is an oral liquid dosage form.
- the PD-L1 antibody is Durvalumab
- the small molecule PD-1/PD-L1 inhibitor is compound 29
- Durvalumab is an intravenous injection dosage form
- Compound 29 is an oral liquid dosage form.
- the PD-L1 antibody is Durvalumab
- the small molecule PD-1/PD-L1 inhibitor is compound 29
- Durvalumab is in the form of subcutaneous injection; compound 29 is compound 29 with 10% (w/v) polyoxyethylene hydrogenated castor oil 40, 20% (w/v) sulfobutyl ether- ⁇ -cyclodextrin and 70% water Suspension.
- the pharmaceutical composition can be presented in a unit dosage form containing a predetermined amount of active ingredient per unit dose.
- the amount of active ingredient per dose depends on the condition being treated, the route of administration, and the age, weight and condition of the patient.
- Preferred unit dose compositions contain a single dose, daily dose or sub-dose of the active ingredient, or suitable portions thereof.
- this pharmaceutical composition can be prepared by any method well known in the pharmaceutical art.
- the content of the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor in the unit dosage form of the pharmaceutical composition is a therapeutically effective amount.
- the content ratio of the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor in the unit dosage form of the pharmaceutical composition may be 1:1-1:9, such as 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8 or 1:9.
- the present invention provides an application of the pharmaceutical composition as described herein in the preparation of a medicine for treating cancer.
- the present invention provides a method of treating cancer, which comprises administering a therapeutically effective amount of a pharmaceutical composition as described herein to a subject in need thereof.
- the cancer is lung cancer, gastric cancer, colorectal cancer, cervical cancer, ovarian cancer, prostate cancer, breast cancer, pancreatic cancer, liver cancer, bladder cancer, kidney cancer, bone cancer, skin cancer, melanoma, Glioma, glioblastoma, leukemia or lymphoma.
- the cancer is lung cancer, colorectal cancer, breast cancer, melanoma, leukemia, or lymphoma.
- the cancer is colorectal cancer.
- the cancer is colon cancer.
- the dosage regimen of the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor can be adjusted by those skilled in the art as needed to provide the optimal The therapeutic effect.
- the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor can be administered simultaneously or separately (for example, sequential administration).
- the "simultaneous administration” means that the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor can be in a single pharmaceutical composition containing the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor Simultaneous application and combined use.
- the "separate administration” means that the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor can be administered separately in each of the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor.
- the pharmaceutical composition is administered separately in a sequential manner, for example, the PD-L1 antibody or the small molecule PD-1/PD-L1 inhibitor is administered first and the other is administered second.
- Such sequential administration can be close in time (e.g. simultaneously) or distant in time.
- the PD-L1 antibody can be administered by any suitable route in the art, including oral, injection (for example, intravenous, intramuscular, subcutaneous) and the like.
- the PD-L1 antibody is administered by injection.
- the PD-L1 antibody is administered by intravenous injection.
- the PD-L1 antibody is administered by subcutaneous injection.
- the PD-L1 antibody is Durvalumab, which is administered by injection.
- the PD-L1 antibody is Durvalumab, which is administered by intravenous injection.
- the PD-L1 antibody is Durvalumab, which is administered by subcutaneous injection.
- the PD-L1 antibody (such as Durvalumab) can be administered according to the weight of the subject, and a non-limiting example range can be 1.0-1000 mg/kg, such as 10-150 mg/kg, such as 5 mg/kg, 10 mg/kg, 15mg/kg, 20mg/kg, 30mg/kg, 40mg/kg, 50mg/kg, 60mg/kg, 70mg/kg, 80mg/kg, 90mg/kg, 100mg/kg, 110mg/kg, 120mg/kg or 150mg/ kg. In some embodiments, the dose of PD-L1 antibody is 20 mg/kg.
- the above dosage can be QD (once a day), BID (twice a day), TID (three times a day), QOD (one day apart), QW (once a week), BIW (twice a week) or Q2W (once every two weeks), etc. Dosing frequently.
- the PD-L1 antibody is administered at BIW frequency.
- the PD-L1 antibody (for example, Durvalumab) is administered by injection (for example, intravenous injection, subcutaneous injection) according to the above-mentioned dosage and frequency.
- the PD-L1 antibody is Durvalumab, which is administered by injection (for example, intravenous injection, subcutaneous injection) at a dose of 20 mg/kg according to the BIW frequency.
- the PD-L1 antibody (for example, Durvalumab) can also be administered to the subject in a fixed dose, that is, a fixed or predetermined amount of dose is given to the subject.
- the small molecule PD-1/PD-L1 inhibitor can be administered by any suitable route in the art, including oral, injection (for example, intravenous, intramuscular, subcutaneous) and the like.
- the small molecule PD-1/PD-L1 inhibitor is administered orally.
- the small molecule PD-1/PD-L1 inhibitor is compound 29 and is administered orally.
- the dosage regimen of the small molecule PD-1/PD-L1 inhibitor can be adjusted as needed to provide the best therapeutic effect.
- the small molecule PD-1/PD-L1 inhibitor (such as compound 29) can be administered according to the weight of the subject, and a non-limiting example can range from 1.0-1000 mg/kg, such as 5-180 mg/kg, for example 5mg/kg, 10mg/kg, 15mg/kg, 20mg/kg, 30mg/kg, 40mg/kg, 50mg/kg, 60mg/kg, 70mg/kg, 80mg/kg, 90mg/kg, 100mg/kg, 110mg/ kg, 120mg/kg or 150mg/kg.
- 1.0-1000 mg/kg such as 5-180 mg/kg, for example 5mg/kg, 10mg/kg, 15mg/kg, 20mg/kg, 30mg/kg, 40mg/kg, 50mg/kg, 60mg/kg, 70mg/kg, 80mg/kg, 90mg/kg, 100mg/kg, 110mg/ kg, 120mg/kg or 150mg
- the dose of the small molecule PD-1/PD-L1 inhibitor is 15-180 mg/kg, such as 30-120 mg/kg, such as 60-120 mg/kg.
- the above dosage can be QD (once a day), BID (twice a day), TID (three times a day), QOD (one day apart), QW (once a week), BIW (twice a week) or Q2W (once every two weeks) Dosing frequently.
- small molecule PD-1/PD-L1 inhibitors are administered as frequently as BID.
- the small molecule PD-1/PD-L1 inhibitor (for example, Compound 29) is administered orally according to the above-mentioned dosage and frequency.
- the small molecule PD-1/PD-L1 inhibitor is compound 29, which is administered orally at a dose of 60 mg/kg according to the frequency of BID.
- the small molecule PD-1/PD-L1 inhibitor (such as compound 29) can also be administered to the subject in a fixed dose, that is, a fixed or predetermined amount of dose is given to the subject.
- the PD-L1 antibody is Durvalumab, which is administered by injection (for example, intravenous injection, subcutaneous injection) at a dose of 20 mg/kg according to the BIW frequency; and,
- the small molecule PD-1/PD-L1 inhibitor is compound 29, which is administered orally at a dose of 60 mg/kg according to the frequency of BID.
- the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor are administered separately, the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor can be continuously administered according to their respective administration cycles Administration.
- the administration cycle of the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor can start at the same time or at different times.
- the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor can be administered continuously on the same day according to their respective dosing cycles; or, the small molecule PD-1/PD-L1 inhibitor can be administered in PD -L1 antibody is administered on the second day or on the third day or more after the start of administration, and then both are administered continuously according to their respective administration cycles.
- the pharmaceutical composition described herein can be presented in the form of a combination kit (or called a kit of parts).
- kit or “kit of parts” as used herein refers to a container for administering one or more pharmaceutical compositions of the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor.
- the combination kit can include the PD-L1 antibody and the small molecule PD-L1 in a single pharmaceutical composition or a separate pharmaceutical composition. 1/PD-L1 inhibitor.
- the combination kit will contain a separate first pharmaceutical composition containing PD-L1 antibody and a small molecule PD-1 /PD-L1 inhibitor of the second pharmaceutical composition.
- the combination kit comprises:
- a pharmaceutically acceptable carrier is selected from:
- the PD-L1 antibody and the small molecule PD-1/PD-L1 inhibitor are provided in a form suitable for simultaneous administration and/or separate administration.
- the combination kit comprises:
- a first container comprising a first pharmaceutical composition, the first pharmaceutical composition comprising a PD-L1 antibody and a pharmaceutically acceptable carrier;
- a second container which contains a second pharmaceutical composition, the second pharmaceutical composition comprising a small molecule PD-1/PD-L1 inhibitor or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- compositions described herein can be used alone or in combination with one or more other therapeutic agents (eg, immunomodulators, other anti-tumor agents, etc.). Therefore, the pharmaceutical composition described herein may include PD-L1 antibodies, small molecule PD-1/PD-L1 inhibitors, and optionally other therapeutic agents. This combination of agents can be administered together or separately, and when administered separately, they can be administered simultaneously or sequentially in any order that is close in time and distant in time.
- therapeutic agents eg, immunomodulators, other anti-tumor agents, etc.
- the pharmaceutical composition described herein may include PD-L1 antibodies, small molecule PD-1/PD-L1 inhibitors, and optionally other therapeutic agents. This combination of agents can be administered together or separately, and when administered separately, they can be administered simultaneously or sequentially in any order that is close in time and distant in time.
- composition described herein can also be used together with other treatment methods for cancer treatment (for example, chemotherapy, surgery and/or radiation therapy, etc.).
- small molecule PD-1/PD-L1 inhibitor refers to any small molecule compound that can directly or indirectly reduce or inhibit (partially or completely) the activity of the PD-L1/PD-1 pathway, which can be expressed as " Small molecule PD-1/PD-L1 pathway inhibitor".
- Small molecule PD-1/PD-L1 inhibitors can inhibit the interaction of PD-1, PD-L1, and/or PD-1/PD-L1.
- small molecules should be understood as a concept opposite to biological macromolecules, that is, small molecules do not include biological macromolecular drugs (such as antibodies), which should not be understood as unclear.
- antibody as used herein is intended to include whole molecules as well as fragments that contain an antigen binding site and can bind to an epitope.
- PD-L1 as used herein includes isotypes, mammalian, such as human PD-L1, species homologs of human PD-L1, and analogs containing at least one common epitope with PD-L1.
- the amino acid sequence of PD-L1, such as human PD-L1, is known in the art.
- homologous refers to the subunit sequence identity between two polymeric molecules, for example, between two nucleic acid molecules, such as between two DNA molecules or two RNA molecules, or between two polypeptide molecules. between.
- two molecules are occupied by the same monomer subunit at a subunit position, for example, if two DNA molecules are each occupied by adenine at a position, then they are homologous or identical at that position of.
- the homology between two sequences is a direct function of the number of matches or homologous positions; for example, if half of the positions in the two sequences (for example, five positions in a ten subunit long polymer) are homologous , The two sequences are 50% homologous; if 90% of the positions (for example, 9 out of 10) are matched or homologous, the two sequences are 90% homologous.
- P-L1 antibody as used herein may be polyclonal or monoclonal.
- monoclonal antibody refers to those that exhibit binding specificity and affinity to only a single specific epitope.
- Monoclonal antibodies can be prepared by hybridoma technology or methods that do not use hybridoma technology (such as recombinant methods).
- the PD-L1 antibodies described herein may be humanized.
- the term "humanized” refers to a non-human (e.g., murine) antibody form containing minimal sequences derived from non-human immunoglobulins, which may be chimeric immunoglobulins, immunoglobulin chains or fragments thereof.
- the PD-L1 antibody described herein also includes a homology of more than 80%, preferably more than 90%, more preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98 % Or more than 99% of antibody molecules.
- treatment refers to therapeutic therapy.
- treatment refers to: (1) alleviating one or more biological manifestations of the disease or disease, (2) interfering with (a) one or more points in the biological cascade causing or causing the disease, or (b) ) One or more biological manifestations of the disease, (3) Improve one or more symptoms, effects or side effects related to the disease, or one or more symptoms, effects or side effects related to the disease or its treatment, Or (4) to slow down the development of the disease or one or more biological manifestations of the disease.
- the compounds of the invention are administered as a preventive measure.
- preventing or “preventing” refers to reducing the risk of acquiring a given disease or condition.
- the designated compound is administered to a subject as a preventive measure, such as a subject with a family history or tendency of cancer or autoimmune disease.
- terapéuticaally effective amount refers to an amount of a compound that is sufficient to effectively treat the diseases or conditions described herein when administered to a subject.
- the amount of the compound constituting the “therapeutically effective amount” will vary according to the compound, the condition and its severity, the age of the subject to be treated, the compound dosage form, the mode of administration, the interval of administration, etc., but can be determined by those skilled in the art as required Make sure.
- administration refers to the subject's administration of one or more substances (for example, PD-L1 antibody and/or PD-L1 small molecule inhibitor), which can also be expressed as “administration”.
- substances for example, PD-L1 antibody and/or PD-L1 small molecule inhibitor
- pharmaceutical composition (pharmaceutical composition) used herein can also be expressed as “pharmaceutical combination”, and the two can be substituted for each other in this document.
- dose refers to a single dose.
- container refers to any container and closure suitable for storing, transporting, dispensing and/or handling pharmaceuticals.
- pharmaceutically acceptable refers to salts, compositions, excipients and the like that are generally non-toxic, safe, and suitable for use by subjects, preferably mammalian subjects, more preferably human subjects.
- subject or “patient” as used herein refers to any animal that is about to or has received administration of the compound or composition according to an embodiment of the present invention, mammals are preferred, and humans are preferred.
- mammal includes any mammal. Examples of mammals include, but are not limited to, cattle, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., with humans being the most preferred.
- subject and patient are used interchangeably herein.
- salts include, but are not limited to: sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinic acid Salt, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate , Fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate , P-toluenesulfonate and pamoate (i.e.
- Suitable alkali salts include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, bismuth, and diethanolamine salts.
- Suitable alkali salts include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, bismuth, and diethanolamine salts.
- halogen as used herein is preferably F, Cl, Br or I.
- substituted or unsubstituted alkyl group is preferably a substituted or unsubstituted C 1 -C 4 alkyl with.
- the substituted or unsubstituted C 1 -C 4 alkyl group is preferably substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted n-propyl, substituted or unsubstituted isopropyl , Substituted or unsubstituted n-butyl, substituted or unsubstituted isobutyl, or, substituted or unsubstituted tert-butyl.
- substituted or unsubstituted alkoxy is preferably a substituted or unsubstituted C 1 -C 4 alkoxy group.
- the substituted or unsubstituted C 1 -C 4 alkoxy group is preferably substituted or unsubstituted methoxy, substituted or unsubstituted ethoxy, substituted or unsubstituted n-propoxy, substituted or unsubstituted
- alkylthio as used herein is preferably -SR s , where R s is a C 1 -C 4 alkyl group.
- C 1-4 alkyl as used herein is preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl.
- C 1-4 alkoxy as used herein is preferably methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy.
- C 1-4 carboxyl as used herein is preferably
- C 1-4 ester group used herein is preferably Wherein, R 2a is a C 1- C 4 alkyl group.
- R 1b is hydrogen or C 1- C 4 alkyl.
- heteromatic ring used herein is preferably a C 1 -C 10 heteroaromatic ring, more preferably an acridine ring, a carbazole ring, a cinnoline ring, a carboline ring, a quinoxaline ring, an imidazole ring, a pyrazole ring, a pyrrole Ring, indole ring, indoline ring, benzotriazole ring, benzimidazole ring, furan ring, thiophene ring, isothiazole ring, benzothiophene ring, dihydrobenzothiophene ring, benzofuran ring, Isobenzofuran ring, benzoxazole ring, benzofuran ring, benzopyrazole ring, quinoline ring, isazaindene ring, isoquinoline ring, oxazole ring, oxadiazole
- 5-7 membered carbocyclic ring refers to a 5-7 membered carbocyclic ring where the heteroatom is oxygen and/or nitrogen, and the number of heteroatoms is 1-4. There are 5, 6 or 7 ring atoms in the 5-7 membered carbon heterocyclic ring.
- the 5-7 membered carbocyclic ring includes but is not limited to: azetidine ring, piperazine ring, piperidine ring, pyrrole ring, morpholine ring, thiomorpholine ring, 1,4-dioxane ring , Pyran ring, dihydroimidazole ring, dihydroisoxazole ring, dihydroisothiazole ring, dihydrooxadiazole ring, dihydrooxazole ring, dihydropyrazine ring, dihydropyrazole ring, dihydro Pyridine ring, dihydropyrimidine ring, dihydropyrrole ring, dihydroquinoline ring, dihydrotetrazole ring, dihydrothiadiazole ring, dihydrothiazole ring, dihydrotriazole ring, dihydroazetidine ring , Imidazole ring, pyrazole ring, pyrrol
- pharmaceutically acceptable carrier refers to any preparation or carrier medium that can deliver an active substance, does not interfere with the biological activity of the active substance, and has no toxic side effects to the host or patient.
- the pharmaceutical composition can be made into various types of administration unit dosage forms, such as tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories and injections (solutions and Suspension), etc., preferably liquid, suspension, emulsion, suppository, injection (solution and suspension), etc.
- any excipient known and widely used in the art can be used.
- carriers such as lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose and silicic acid, etc.
- binders such as water, ethanol, propanol, ordinary syrup, glucose solution, starch Solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose and potassium phosphate, polyvinylpyrrolidone, etc.
- disintegrant such as dry starch, sodium alginate, agar powder and kelp powder, sodium bicarbonate, carbonic acid Fatty acid esters of calcium, polyethylene sorbitan, sodium lauryl sulfate, monoglyceride stearate, starch and lactose, etc.
- disintegration inhibitors such as white sugar, glyceryl tristearate, coconut oil and hydrogenated Oil
- adsorption promoters such as
- any known and widely used excipients in the art can be used, for example, carriers such as lactose, starch, coconut oil, hardened vegetable oil, kaolin and talc; binders , Such as gum arabic powder, gum tragacanth powder, gelatin and ethanol; disintegrants such as agar and kelp powder.
- carriers such as lactose, starch, coconut oil, hardened vegetable oil, kaolin and talc
- binders Such as gum arabic powder, gum tragacanth powder, gelatin and ethanol
- disintegrants such as agar and kelp powder.
- any excipients known and widely used in the art can be used, for example, polyethylene glycol, coconut oil, higher alcohols, esters of higher alcohols, gelatin and semi-synthetic glycerides, etc. .
- the solution or suspension can be sterilized (preferably by adding an appropriate amount of sodium chloride, glucose or glycerin, etc.) to prepare an injection that is isotonic with blood.
- any carriers commonly used in the art can also be used.
- usual dissolving agents, buffers and analgesics can also be added.
- the diluent may be a conventional diluent in the art.
- the pharmaceutical composition may be in the form of oral or sterile injectable aqueous solution, and the oral or injection composition may be prepared according to any method known in the art for preparing pharmaceutical compositions.
- the term "prodrug” refers to a derivative of a compound containing a biologically reactive functional group, such that under biological conditions (in vitro or in vivo), the biologically reactive functional group can be cleaved from the compound or otherwise reacted to provide the The compound.
- the prodrug is inactive, or at least less active than the compound itself, so that the compound cannot exert its activity until the compound is cleaved from the biologically reactive functional group.
- the bioreactive functional group can be hydrolyzed or oxidized under biological conditions to provide the compound.
- the prodrug may contain a biohydrolyzable group.
- biohydrolyzable groups include, but are not limited to, biohydrolyzable phosphate, biohydrolyzable ester, biohydrolyzable amide, biohydrolyzable carbonate, biohydrolyzable carbamate, and biohydrolyzable Urea.
- stereoisomers refers to cis- and trans-isomers, R- and S-enantiomers, and diastereomers.
- stereoisomer refers to cis- and trans-isomers, R- and S-enantiomers, and diastereomers.
- These stereoisomers can be prepared by asymmetric synthesis methods or chiral separation methods (for example, separation, crystallization, thin layer chromatography, column chromatography, gas chromatography, high performance liquid chromatography).
- stereoisomers can also be derived from diastereomers in which a mixture of enantiomers or racemates are reacted with a suitable chiral compound, and then obtained by crystallization or any other suitable conventional method.
- the compound of the present invention may also include its metabolites.
- the term "metabolite” as used herein refers to the active substance produced after the chemical structure of the drug molecule undergoes changes in the body.
- the active substance is generally a derivative of the aforementioned drug molecule, which can also be chemically modified.
- the compound of the present invention may also include its polymorph.
- crystal form refers to one or more crystal structures formed by different arrangements of molecules in the lattice space during crystallization.
- the compound of the present invention may also include its solvate.
- solvate refers to a crystalline form of a compound, its pharmaceutically acceptable salt, crystal form, co-crystal, stereoisomer, isotopic compound, metabolite or prodrug, and it also contains one or A variety of solvent molecules incorporated into the crystal structure.
- Solvates may include stoichiometric or non-stoichiometric amounts of solvent, and solvent molecules in the solvent may exist in an ordered or non-ordered arrangement.
- a solvate containing a non-stoichiometric amount of solvent molecules may result from the solvate losing at least a portion (but not all) of the solvent molecules.
- a solvate is a hydrate, meaning that the crystalline form of the compound further includes water molecules.
- the compounds of the present invention may also include their prodrugs.
- prodrug refers to a derivative of a compound containing a biologically reactive functional group, such that under biological conditions (in vitro or in vivo), the biologically reactive functional group can be cleaved from the compound or otherwise react to provide the compound.
- the prodrug is inactive, or at least less active than the compound itself, so that the compound cannot exert its activity until the compound is cleaved from the biologically reactive functional group.
- the bioreactive functional group can be hydrolyzed or oxidized under biological conditions to provide the compound.
- the prodrug may contain a biohydrolyzable group.
- biohydrolyzable groups include, but are not limited to, biohydrolyzable phosphate, biohydrolyzable ester, biohydrolyzable amide, biohydrolyzable carbonate, Biohydrolyzable carbamates and biohydrolyzable ureas.
- the compounds of the present invention may also include isotopic derivatives thereof.
- isotopic derivative refers to the compound containing one or more natural or unnatural abundance atomic isotopes. Atomic isotopes of unnatural abundance include but are not limited to deuterium ( 2 H or D), tritium ( 3 H or T), iodine-125 ( 125 I), phosphorus-32 ( 32 P), carbon-13 ( 13 C) Or carbon-14 ( 14 C). All isotopic variants of the compounds of the present invention, whether radioactive or not, are included within the scope of the present invention.
- the compound codes used herein such as KN035, CS1001, MBS2311, BGB-A333, KL-A167, SHR-1316, STI-A1014, etc., are all known in the art.
- the reagents and raw materials used in the present invention are all commercially available.
- the positive progress effect of the present invention is to provide a small molecule PD-1/PD-L1 inhibitor or a pharmaceutical composition with PD-L1 antibody, which can be used to treat cancer.
- Fig. 1 is a graph showing the change in body weight of mice in each group in effect example 3.
- Fig. 2 is a graph showing the rate of change in body weight of mice in each group in Effect Example 3.
- Fig. 3 is a graph showing the tumor volume growth curve of each group of mice in Effect Example 3.
- Figure 4 is a graph showing the tumor inhibition rate of each group of mice in Effect Example 3.
- room temperature refers to 10°C-30°C
- reflux refers to the solvent reflux temperature
- overnight refers to 8-24 hours, preferably 12-18 hours.
- the structure of the compound is determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS).
- NMR nuclear magnetic resonance
- MS mass spectrometry
- the nuclear magnetic resonance spectrum is obtained by Bruker Avance-500 instrument. Deuterated dimethyl sulfoxide, deuterated chloroform and deuterated methanol are used as solvents. Tetramethyl Silane (TMS) is an internal standard.
- TMS Tetramethyl Silane
- the mass spectrum was obtained by a liquid chromatography-mass spectrometry (LC-MS) combined instrument Agilent Technologies 6110, using an ESI ion source.
- the microwave reaction is carried out in the Explorer automatic microwave synthesizer produced by CEM, USA.
- the magnetron frequency is 2450MHz and the continuous microwave output power is 300W.
- the instrument used for HPLC preparation is Gilson 281, and the preparation column used is Shimadazu Shim-Pack, PRC-ODS, 20x250mm, 15 ⁇ m.
- 1,4-dioxane-6-phenylboronic acid (3.60g, 20mmol) and 2,6-dibromotoluene (7.50g, 30mmol) were dissolved in 1,4-dioxane (100mL) and water ( 15 mL) was added to the mixed solution of [1,1'-bis(diphenylphosphorferrocene)] palladium dichloride dichloromethane complex (817 mg, 1 mmol) and sodium carbonate (6.38 g, 60 mmol). After the reaction system was replaced with nitrogen three times, it was heated to 80°C and stirred for 16 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (petroleum ether) to obtain compound 1-c (2.70 g, yield: 44%).
- ⁇ -(Hydroxymethyl)serine (135mg, 1mmol) was dissolved in water (3mL) and 1M sodium hydroxide (2mL) in an aqueous solution, compound 3-b (110mg, 0.3mmol) in tetrahydrofuran (3mL) and In a mixed solution of ethanol (5 mL), the mixture was stirred at room temperature for 16 hours. The reaction solution was cooled to 0°C, sodium borohydride (38 mg, 1 mmol) was added, and stirring was continued for 1 hour.
- a homogeneous time-resolved fluorescence (Homogenouse Time-Resolved Fluorescence, HTRF) binding test is used to detect the binding ability of the compound of the present invention to PD-1/PD-L1.
- the purchased kit contains the reagents needed for experiments such as PD-1, PD-L1, anti-tag1-Eu, Anti-tag2-XL665, Dilute Buffer and Detection Buffer.
- the compound is configured with 100% DMSO into 10 concentrations with a concentration gradient of 3 times.
- the internal standard Glipizide (Glipizide, molecular formula C 21 H 27 N 5 O 4 S, molecular weight 445.5 g/mol, analytical grade) was purchased from Sigma-Aldrich (USA). Methanol, acetonitrile, and formic acid (HPLC grade) were purchased from Sigma-Aldrich Company (USA), and pure water was purchased from Hangzhou Wahaha Group Co., Ltd. (Hangzhou, China). Other chemical reagents are of analytical grade.
- WinNonlin 6.4 software USA was used to calculate the pharmacokinetic parameters of the compound according to the non-compartmental model.
- mice pharmacokinetic results of the compound of the present invention are as follows (Table 2):
- Antibody PD-L1 antibody Imfinzi (Durvalumab), specification 120mg/2.4mL (50mg/mL), Lot: 041E17C.
- Manufacturer AstraZeneca, purchased from Hong Kong Mingchuang Pharmaceutical Co., Ltd., and stored at 2-8°C.
- mice human PD-1 transgenic mice, strain: C57BL/6-hPD-1 mice, 6-8 weeks, weighing 18-21 grams, female, 120, purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. .
- Cremophor RH40 (CAS: 61788-85-0, Lot: 29761847G0, supplier: Shanghai Xietai Chemical Co., Ltd.); SBE- ⁇ -CD (CAS: 128446-35-5, Lot: R1804474, supplier: Shanghai Shaoyuan Reagent Co., Ltd.); DMEM (CAS: 11995-065, Lot: 2025378, supplier: Gibco); Penicillin double antibody (CAS: 15140-122, Lot: 1953101, supplier: Hyclone); Bovine serum (CAS: 10099-141, Lot: 1966174C, supplier: Gibco); hygromycinB (CAS: 10687010, Lot: HY069-L12, supplier: Invitrogen).
- MC-38-hPD-Ll cells Human PD-L1 gene knocked into MC-38 cells adhered culture in vitro, the culture conditions are DMEM medium with 10% heat-inactivated fetal bovine serum, and hygromycinB (final concentration 100 ⁇ L/mL), incubated at 37°C with 5% CO 2 . Passage treatment three times a week. When the cells are in the exponential growth phase, the cells are collected and counted. 100 ⁇ L of 1 ⁇ 106 MC-38-hPD-L1 cell suspension was inoculated subcutaneously on the right dorsal side of C57BL/6-hPD-1 mice.
- tumor-bearing mice Six days after inoculation, 60 tumor-bearing mice with transplanted tumor volume ranging from 31.49mm 3 -110.26mm 3 were selected. According to the experimental plan, the tumor-bearing mice were randomly divided into 6 groups, each with 10 mice, and the administration was started on the same day.
- Solvent preparation Measure 800mL of sterile water into the volumetric flask, turn on the magnetic stirring to make the liquid surface have a vortex, slowly add 100g of Cremophor RH40 medicine spoon into the vortex, continue to stir until the solution is clear, then slowly add 200g The SBE- ⁇ -CD is continuously stirred until the solution is clear, and the final volume is adjusted to 1000 mL to obtain an aqueous solution containing 10% (w/v) Cremophor RH40+20% (w/v) SBE- ⁇ -CD.
- Preparation of compound 29 suspension weigh 150.92 mg of compound 29, add 12.5 mL of 10% (w/v) Cremophor RH40 + 20% (w/v) SBE- ⁇ -CD aqueous solution (hereinafter referred to as solvent), vortex Rotate for 2 minutes to mix well, and ultrasonic for 30 minutes to obtain a suspension solution with a concentration of 12.0 mg/mL.
- solvent 10% (w/v) Cremophor RH40 + 20% (w/v) SBE- ⁇ -CD aqueous solution (hereinafter referred to as solvent), vortex Rotate for 2 minutes to mix well, and ultrasonic for 30 minutes to obtain a suspension solution with a concentration of 12.0 mg/mL.
- Aspirate 5.0 mL of the compound 29 suspension solution with a concentration of 12.0 mg/mL add 5.0 mL of the solvent solution, vortex for 1 minute to mix well, and sonicate for 5 minutes to obtain a suspension solution with a concentration of 6.0 mg/mL.
- Preparation of PD-L1 antibody Pipette 0.12mL of Durvalumab stock solution (concentration: 50mg/mL), divide into 6 aliquots in 5mL sterile centrifuge tubes, each with a content of 6.0mg, and place the aliquots in a refrigerator at 4°C for later use. Before administration, take a 0.12mL stock solution with a concentration of 50mg/mL, add 2.88mL 0.9% sodium chloride solution, vortex slightly to mix the solution completely, and obtain 3mL of Durvalumab solution with a final concentration of 2mg/mL.
- mice in the vehicle control group were weighed and recorded on an electronic balance according to their numbers.
- the mice were given the vehicle by gavage twice a day, with a capacity of 0.1mL/10g, and each mouse took about 20 seconds.
- Each group It takes about 5 minutes to share with 10 animals.
- mice in the compound 29 (30mg/kg) group were weighed and recorded on an electronic balance according to their numbers.
- the compound 29 suspension was given by gavage twice a day according to the mouse body weight, and the compound 29 was given at 30 mg/kg.
- Medicine, the administration volume is 0.1mL/10g, it takes about 20 seconds for each mouse, and about 5 minutes for each group of 10 mice.
- mice in the compound 29 (60mg/kg) group were weighed and recorded on an electronic balance according to their numbers.
- the compound 29 suspension was administered by gavage twice a day according to the mouse body weight, and the compound 29 suspension was administered at 60 mg/kg.
- Medicine, the administration volume is 0.1mL/10g, it takes about 20 seconds for each mouse, and about 5 minutes for each group of 10 mice.
- mice in the compound 29 (120mg/kg) group were weighed and recorded on an electronic balance according to their numbers, and the compound 29 suspension was given by gavage twice a day according to the weight of the mice, and the compound 29 was given at 120 mg/kg.
- Medicine, the administration volume is 0.1mL/10g, it takes about 20 seconds for each mouse, and about 5 minutes for each group of 10 mice.
- mice in the combined drug (compound 29: 60mg/kg; Durvalumab: 20mg/kg) group were weighed and recorded on an electronic balance according to their numbers, and the compound was given by intragastric administration twice a day according to the weight of the mice
- the 29 suspension is administered at 60 mg/kg with a dosage volume of 0.1 mL/10 g. It takes about 20 seconds for each mouse, and about 5 minutes for each group of 10 mice.
- mice in the combined drug (compound 29: 60mg/kg; Durvalumab: 20mg/kg) group were weighed and recorded on an electronic balance according to their numbers, and the formulated Durvalumab was injected into the abdominal cavity according to the mouse body weight at 20 mg/kg It is administered twice a week, with a volume of 0.1mL/10g. It takes about 20 seconds for each mouse, and about 5 minutes for each group of 10 mice.
- Figure 1 is a graph of the weight change of each group of mice, drawn from the average weight of each group of mice measured daily during the experiment.
- Figure 2 is a graph of the relative change rate of body weight of each group of mice, drawn from the average of the daily body weight change rate of each group of mice during the experiment.
- Figure 3 is a graph of the tumor volume growth curve of each group of mice, drawn from the average value of the tumor volume measured by each group of mice during the experiment.
- Figure 4 is a graph of the tumor inhibition rate of each group of mice, drawn from the average value of the tumor inhibition rate calculated for each group of mice during the experiment.
- P value is calculated based on tumor volume (compared with solvent control group).
- the experimental results showed that, compared with the vehicle control group, the tumor inhibition rate of group 2 (PD-L1 antibody Durvalumab) was 48.17%, the maximum tumor inhibition rate of compound 29 was 51.21%, and the inhibition rate of the combination group was 51.21%. The tumor rate was 62.82%. From this, the following conclusions can be drawn: The inhibitory effect of the combination group on colon cancer (MC-38-hPD-L1) cells is significantly better than that of single component compound 29 or PD-L1 antibody, which can be significant Increase the tumor inhibition rate in mice, and has statistical significance.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
化合物 | IC 50(μM) | 化合物 | IC 50(μM) |
1 | 0.014 | 2 | 3.1 |
3 | 0.046 | 5 | 0.023 |
6 | 0.32 | 7 | 1.4 |
8 | 0.042 | 9 | 0.057 |
12 | 0.024 | 13 | 0.013 |
14 | 0.019 | 15 | 0.014 |
16 | 0.013 | 17 | 0.020 |
18 | 0.046 | 19 | 0.061 |
20 | 0.018 | 21 | 0.085 |
22 | 0.044 | 23 | 0.026 |
24 | 0.430 | 25 | 0.066 |
26 | 0.020 | 27 | 0.018 |
28 | 0.029 | 29 | 0.019 |
30 | 0.027 | 31 | 0.041 |
32 | 0.024 | 33 | 0.230 |
34 | 0.180 | 35 | 1.1 |
36 | >10 | 37 | 1.3 |
38 | >10 | 39 | 2.2 |
40 | 0.580 | 41 | 0.540 |
42 | 0.880 | 43 | 0.540 |
Claims (21)
- 一种药物组合物,其包含:PD-L1抗体;和,小分子PD-1/PD-L1抑制剂或其药学上可接受的盐。
- 如权利要求1所述的药物组合物,其特征在于:所述PD-L1抗体为Atezolizumab、Durvalumab、Avelumab、Cemiplimab、KN035、CS1001、MBS2311、BGB-A333、KL-A167、SHR-1316和STI-A1014中的一种或多种。
- 如权利要求2所述的药物组合物,其特征在于:所述PD-L1抗体为Durvalumab。
- 如权利要求1-3中任一项所述的药物组合物,其特征在于:所述小分子PD-1/PD-L1抑制剂为芳香乙烯或芳香乙基类衍生物、其药学上可接受的盐、氘代物、代谢产物、代谢前体或药物前体;和/或,所述小分子PD-1/PD-L1抑制剂的分子量小于1500道尔顿;和/或,所述小分子PD-1/PD-L1抑制剂在PD-1/PD-L1结合实验中具有小于100nM的IC 50值;和/或,所述小分子PD-1/PD-L1抑制剂与PD-L1结合。
- 如权利要求1-4中任一项所述的药物组合物,其特征在于:所述小分子PD-1/PD-L1抑制剂为通式(I)所示的芳香乙烯或芳香乙基类衍生物、其药学上可接受的盐、氘代物、代谢产物、代谢前体或药物前体:其中:每个R 1相同或不同,各自独立地为氘、卤素、取代或未取代的羟基、取代或未取代的氨基、取代或未取代的烷基、或取代或未取代的烷氧基;或者相邻的两个R 1和与它们相连的两个碳原子共同形成一个5-7元的碳环或碳杂环;所述碳杂环中,杂原子为氧和/或氮,杂原子数为1-4个;R 2为取代或未取代的烷基或卤素;每个R 3相同或不同,各自独立地为氘、卤素、取代或未取代的烷硫基、取代或未取 代的羟基、取代或未取代的氨基、取代或未取代的烷基、取代或未取代的烷氧基、 其中,R 1a为C 1-C 4烷基,或者相邻的两个R 3和与它们相连的两个碳原子共同形成一个5-7元的碳环或碳杂环;所述碳杂环中,杂原子为氧和/或氮,杂原子数为1-4个;当两个R 3相邻,且相邻的两个R 3和与它们相连的两个碳原子共同形成一个5-7元的碳环或碳杂环时,所述的碳环或碳杂环还进一步被C 1-4的烷基中的一个或多个所取代;每个R 1、R 2和每个R 3中所述的取代的烷基、每个R 1和每个R 3中所述的取代的烷氧基,和每个R 3中所述的取代的烷硫基中的取代基选自下列基团中的一个或多个:卤素、C 1-4的烷基、羟基、 C 1-4的烷氧基、C 1-4的羧基、C 1-4的酯基和C 1-4酰胺基;当取代基为多个时,所述的取代基相同或不同;R a和R b独立地为氢、或、取代或未取代的烷基;R a或R b中,所述的取代的烷基中的取代基选自下列基团中的一个或多个:卤素、C 1-C 4烷基、羟基、 C 1-C 4烷氧基、C 1-C 4羧基、C 1-C 4酯基或C 1-C 4酰胺基;R a1和R b1独立地为氢或C 1-C 4的烷基;每个R 1或每个R 3中,所述的取代的羟基或所述的取代的氨基中的取代基选自下列基团中的一个或多个:C 1-4的烷基、C 1-4的烷氧基、C 1-4的羧基、C 1-4的酯基和C 1-4酰胺基;m为1、2、3、4或5;或所述的通式(I)所示的芳香乙烯或芳香乙基类衍生物中, 替换为取代或未取代的杂芳环,所述的杂芳环中的杂原子选自N、O和S,杂原子数为1-4个;所述的取代的杂芳环中的取代基选自下列基团中的一个或多个:卤素、C 1-4的烷基、羟基、 C 1-4的烷氧基、C 1-4的羧基、C 1-4的酯基和C 1-4酰胺基;当取代基为多个时,所述的取代基相同或不同;R a和R b独立地为氢、或、取代或未取代的烷基;R a或R b中,所述的取代的烷基中的取代基选自下列基团中的一个或多个:卤素、C 1-C 4烷基、羟基、 C 1-C 4烷氧基、C 1-C 4羧基、C 1-C 4酯基或C 1-C 4酰胺基;R a1和R b1独立地为氢或C 1-C 4的烷基;所述的通式(I)所示的芳香乙烯或芳香乙基类衍生物不为下列化合物:
- 如权利要求5所述的药物组合物,其特征在于,当每个R 1、R 2和每个R 3中所述的取代的烷基、每个R 1和每个R 3中所述的取代的烷氧基、每个R 3中所述的取代的烷硫基和所述的杂芳环中的取代基选自卤素时,所述的卤素为F、Cl、Br或I;和/或,当每个R 1、R 2和每个R 3中所述的取代的烷基,每个R 1和每个R 3中所述的取代的烷氧基、所述的取代的羟基或所述的取代的氨基、每个R 3中所述的取代的烷硫基、所述的取代的杂芳环和取代的5-7元的碳杂环中的取代基选自C 1-4的烷基时,所述的C 1- 4的烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基;和/或,当每个R 1、R 2和每个R 3中所述的取代的烷基、每个R 1和每个R 3中所述的取代的烷氧基、每个R 3中所述的取代的烷硫基和所述的取代的杂芳环中的取代基选自 R a或R b为卤素时,所述的卤素为F、Cl、Br或I;和/或,当每个R 1、R 2和每个R 3中所述的取代的烷基、每个R 1和每个R 3中所述的取代的烷氧基、每个R 3中所述的取代的烷硫基和所述的取代的杂芳环中的取代基选自 R a或R b为C 1-4的烷基时,所述的C 1-4的烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基;和/或,当每个R 1、R 2和每个R 3中所述的取代的烷基、每个R 1和每个R 3中所述的取代的烷氧基、每个R 3中所述的取代的烷硫基和所述的取代的杂芳环中的取代基选自 R a或R b为 R a1或R b1为C 1-C 4的烷基时,所述的C 1-4的烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基;和/或,当每个R 1、R 2和每个R 3中所述的取代的烷基、每个R 1和每个R 3中所述的取代的烷氧基、每个R 3中所述的取代的烷硫基和所述的取代的杂芳环中的取代基选自 R a或R b为C 1-C 4烷氧基时,所述的C 1-4的烷氧基为甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、异丁氧基或叔丁氧基;和/或,当每个R 1、R 2和每个R 3中所述的取代的烷基、每个R 1和每个R 3中所述的取代的烷氧基、每个R 3中所述的取代的烷硫基和所述的取代的杂芳环中的取代基选自 R a或R b为C 1-C 4羧基时,所述的C 1-C 4羧基为和/或,当每个R 1、R 2和每个R 3中所述的取代的烷基、每个R 1和每个R 3中所述的取代的烷氧基、每个R 3中所述的取代的烷硫基和所述的取代的杂芳环中的取代基选自 R a或R b为C 1-C 4酯基时,所述的C 1-C 4酯基为 R 2a为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基;和/或,当每个R 1、R 2和每个R 3中所述的取代的烷基、每个R 1和每个R 3中所述的取代的烷氧基、每个R 3中所述的取代的烷硫基和所述的取代的杂芳环中的取代基选自 R a或R b为C 1-C 4酰胺基时,所述的C 1-C 4酰胺基为 R 1b为氢、甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基;和/或,当每个R 1、R 2和每个R 3中所述的取代的烷基、每个R 1和每个R 3中所述的取代的烷氧基、所述的取代的羟基或所述的取代的氨基、每个R 3中所述的取代的烷硫基和所述的取代的杂芳环中的取代基选自C 1-C 4烷氧基时,所述的C 1-4的烷氧基为甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、异丁氧基或叔丁氧基;和/或,当每个R 1、R 2和每个R 3中所述的取代的烷基、每个R 1和每个R 3中所述的取代的烷氧基、所述的取代的羟基或所述的取代的氨基、每个R 3中所述的取代的烷硫基和所述的取代的杂芳环中的取代基选自C 1-4的羧基时,所述的C 1-C 4羧基为和/或,当每个R 1、R 2和每个R 3中所述的取代的烷基、每个R 1和每个R 3中所述的取代的烷氧基、所述的取代的羟基或所述的取代的氨基、每个R 3中所述的取代的烷硫基和所述的取代的杂芳环中的取代基选自C 1-C 4酯基时,所述的C 1-C 4酯基为 R 2a为甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基;
- 如权利要求5所述的药物组合物,其特征在于,每个R 1、R 2和每个R 3中,所述的卤素为F、Cl、Br或I;和/或,每个R 1、R 2和每个R 3中,所述的取代或未取代的烷基为取代或未取代的C 1- C 4的烷基;所述的取代或未取代的C 1-C 4的烷基优选取代或未取代的甲基、取代或未取代的乙基、取代或未取代的正丙基、取代或未取代的异丙基、取代或未取代的正丁基、取代或未取代的异丁基、或、取代或未取代的叔丁基;和/或,每个R 1和每个R 3中,所述的取代或未取代的烷氧基为取代或未取代的C 1-C 4的烷氧基;所述的取代或未取代的C 1-C 4的烷氧基优选取代或未取代的甲氧基、取代或未取代的乙氧基、取代或未取代的正丙氧基、取代或未取代的异丙氧基、取代或未取代的正丁氧基、取代或未取代的异丁氧基、或、取代或未取代的叔丁氧基;和/或,每个R 3中,所述的取代或未取代的烷硫基为-S-R s,其中,R s为取代或未取代的C 1-C 4的烷基;所述的取代或未取代的C 1-C 4的烷基优选取代或未取代的甲基、取代或未取代的乙基、取代或未取代的正丙基、取代或未取代的异丙基、取代或未取代的正丁基、取代或未取代的异丁基、或、取代或未取代的叔丁基;和/或,当相邻的两个R 3和与它们相连的两个碳原子共同形成一个5-7元的碳杂环,所述的5-7元碳杂环为氮杂环丁环、哌嗪环、哌啶环、吡咯环、吗啉环、硫代吗啉环、1,4-二氧六环、吡喃环、二氢咪唑环、二氢异噁唑环、二氢异噻唑环、二氢噁二唑环、二氢噁唑环、二氢吡嗪环、二氢吡唑环、二氢吡啶环、二氢嘧啶环、二氢吡咯环、二氢喹啉环、二氢四唑环、二氢噻二唑环、二氢噻唑环、二氢三唑环、二氢氮杂环丁环、咪唑环、吡唑环、吡咯环、呋喃环、噻吩环、异噻唑环、噁唑环、噁二唑环、异噁唑环、吡嗪环、哒嗪环、吡啶环、嘧啶环、四唑环、噻二唑环、噻唑环、噻吩环或三唑环;和/或,当 替换为取代或未取代的杂芳环时,所述的杂芳环为C 1-C 10的杂芳环,所述的杂芳环中的杂原子优选选自N和O,杂原子数为1-3个,所述的杂芳环进一步优选吖啶环、咔唑环、噌啉环、咔啉环、喹喔啉环、咪唑环、吡唑环、吡咯环、吲哚环、二氢吲哚环、苯并三唑环、苯并咪唑环、呋喃环、噻吩环、异噻唑环、苯并噻吩环、二氢苯并噻吩环、苯并呋喃环、异苯并呋喃环、苯并噁唑环、苯并呋咱环、苯并吡唑环、喹啉环、异氮杂茚环、异喹啉环、噁唑环、噁二唑环、异噁唑环、吲哚环、吡嗪环、吡啶并吡啶环、四唑并吡啶环、咪唑并吡啶环、咪唑并吡嗪环、哒嗪环、吡啶环、萘嘧啶环、嘧啶环、四唑环、噻二唑环、噻唑环、噻吩环、三唑环、喹唑啉环、四氢喹啉环、二氢苯 并咪唑环、二氢苯并呋喃环、二氢苯并噁唑环或二氢喹啉环。
- 如权利要求5-7中任一项所述的药物组合物,其特征在于,每个R 1独立地为卤素、或、取代或未取代的烷基;或者相邻的两个R 1和与其相连的两个碳原子共同形成一个5-7元的碳杂环;或者每个R 1独立地为卤素、取代或未取代的烷基、或取代或未取代的烷氧基;和/或,R 2为烷基或卤素;和/或,每个R 3独立地为氘、卤素、烷硫基或烷氧基;或相邻的两个R 3和与它们相连的两个碳原子共同形成一个5-7元的碳杂环;当两个R 3相邻,且相邻的两个R 3和与它们相连的两个碳原子共同形成一个5-7元的碳环或碳杂环时,所述的碳环或碳杂环还可进一步被C 1-4的烷基中的一个或多个所取代;和/或,n为0、1、2、3、4或5;和/或,m为2或3;优选m为2;
- 如权利要求8所述的药物组合物,其特征在于,当R 1为取代的烷基时,所述的取代的烷基中的取代基选自下列基团中的一个或多个:卤素或 R a和R b独立地为氢、或、取代或未取代的烷基;R a或R b中,所述的取代的烷基中的取代基选自下列基团中的一个或多个:羟基或C 1-C 4羧基;和/或,R 1中,所述的取代的烷基、所述取代的烷氧基、所述取代的羟基或所述取代的氨基中的取代基是指被一个或多个卤素取代,优选被一个或多个F取代;和/或,当n为1时,R 3为卤素、烷硫基或烷氧基;且R 3位于苯环的邻位、间位或对位;和/或,当n为2时,两个R 3位于苯环的邻位和间位,两个R 3相同或不同;或者两个R 3相邻,且相邻的两个R 3和与它们相连的两个碳原子共同形成一个5-7元的碳杂环;当两个R 3相邻,且相邻的两个R 3和与它们相连的两个碳原子共同形成一个5-7元的碳环或碳杂环时,所述的碳环或碳杂环还可进一步被C 1-4的烷基中的一个或多个所取代;所述的5-7元的碳杂环优选2,3-二氢-1,4-二氧六环、噁唑环、异噁唑环或吡唑环;和/或,当n为3时,其中两个R 3相邻,且相邻的两个R 3和与它们相连的两个碳原子共同形成一个5-7元的碳杂环;当两个R 3相邻,且相邻的两个R 3和与它们相连的两个 碳原子共同形成一个5-7元的碳环或碳杂环时,所述的碳环或碳杂环还可进一步被C 1-4的烷基中的一个或多个所取代;所述的5-7元的碳杂环优选2,3-二氢-1,4-二氧六环、噁唑环、异噁唑环或吡唑环;和/或,当n为4或5时,R 3为氘;和/或,当m为2时,两个R 1分别位于苯环的邻位和间位,两个R 1相同或不同;位于苯环的邻位的R 1为F、取代或未取代的烷基、或取代或未取代的烷氧基;
- 如权利要求5-10中任一项所述的药物组合物,其特征在于,每个R 1独立地为H、或、取代或未取代的烷基;或者相邻的两个R 1和与其相连的两个碳原子共同形成一个5-7元的碳杂环;所述的取代的烷基中的取代基选自下列基团中的一个或多个:卤素或 R a和R b独立地为氢、或、取代或未取代的烷基;R a或R b中,所述的取代的烷基中的取代基选自下列基团中的一个或多个:羟基或C 1-C 4羧基;R 2为烷基或卤素;每个R 3独立地为H、卤素、烷硫基或烷氧基;或相邻的两个R 3和与它们相连的两个碳原子共同形成一个5-7元的碳杂环;n为0、1、2、3、4或5;当n为1时,R 3为卤素、烷硫基或烷氧基;且R 3位于苯环的邻位、间位或对位;当n为2时,两个R 3位于苯环的邻位和间位,其中,两个R 3相同或不同;或者两个R 3相邻,且相邻的两个R 3和与它们相连的两个碳原子共同形成一个5-7元的碳杂环;当n为3时,其中一个R 3为卤素,另外两个R 3相邻,且相邻的两个R 3和与它们相连的两个碳原子共同形成一个5-7元的碳杂环;当两个R 3相邻,且相邻的两个R 3和与它们相连的两个碳原子共同形成一个5-7元的碳环或碳杂环时,所述的碳环或碳杂环还进一步被C 1-4的烷基中的一个或多个所取代;当n为4或5时,R 3为氘;m为2或3;当m为2时,两个R 1分别位于苯环的邻位和间位,位于苯环邻位的R 1 为烷基或卤素取代的烷基;位于苯环间位的R 1为 取代的烷基;当m为3时,两个R 3相邻,且相邻的两个R 3和与它们相连的两个碳原子共同形成一个5-7元的碳杂环,第三个R 3为 取代的烷基;
- 如权利要求5所述的药物组合物,其特征在于,每个R 1独立地为卤素、取代或未取代的烷基、或取代或未取代的烷氧基;R 2为取代或未取代的烷基或卤素;每个R 1中,所述的取代的烷基、所述的取代的烷氧基、所述的取代的羟基或所述的取代的氨基中的取代基是指被一个或多个卤素取代,优选被一个或多个F取代;每个R 2和每个R 3中所述的取代的烷基、每个R 3中所述的取代的烷氧基和所述的取代的烷硫基中的取代基选自下列基团中的一个或多个:卤素、C 1-4的烷基、羟基、 C 1-4的烷氧基、C 1-4的羧基、C 1-4的酯基和C 1-4酰胺基;当取代基为多个时,所述的取代基相同或不同;R a和R b独立地为氢、或、取代或未取代的烷基;R a或R b中,所述的取代的烷基中的取代基选自下列基团中的一个或多个:卤素、C 1-C 4烷基、羟基、 C 1-C 4烷氧基、C 1-C 4羧基、C 1-C 4酯基或C 1-C 4酰胺基;R a1和R b1独立地为氢或C 1-C 4的烷基;每个R 3中,所述的取代的羟基或所述的取代的氨基中的取代基选自下列基团中的一个或多个:C 1-4的烷基、C 1-4的烷氧基、C 1-4的羧基、C 1-4的酯基和C 1-4酰胺基;m为2或3;n为0、1、2、3、4或5;当m为2时,两个R 1分别位于苯环的邻位和间位,两个R 1相同或不同;位于苯环的邻位的R 1为F、取代或未取代的烷基、或取代或未取代的烷氧基;或所述的通式(I)所示的芳香乙烯或芳香乙基类衍生物中, 替换为取代或未取代的杂芳环,所述的杂芳环中的杂原子选自N、O和S,杂原子数为1-4个;所述的取代的杂芳环中的取代基选自下列基团中的一个或多个:卤素、C 1-4的烷基、羟基、 C 1-4的烷氧基、C 1-4的羧基、C 1-4的酯基和C 1-4酰胺基;当取代基为多个时,所述的取代基相同或不同;R a和R b独立地为氢、或、取代或未取代的烷基;R a或R b中,所述的取代的烷基中的取代基选自下列基团中的一个或多个:卤素、C 1-C 4烷基、羟基、 C 1-C 4烷氧基、C 1-C 4羧基、C 1-C 4酯基或C 1-C 4酰胺基;R a1和R b1独立地为氢或C 1-C 4的烷基。
- 如权利要求16所述的药物组合物,其特征在于:化合物29为口服剂型;和/或,PD-L1抗体为Durvalumab,其为注射剂型。
- 如权利要求1-18中任一项所述的药物组合物,其特征在于:所述药物组合物还包含药学上可接受的载体;和/或,所述PD-L1抗体和小分子PD-1/PD-L1抑制剂存在于单一药物组合物中,或者分别存在于分开的单独药物组合物中。
- 一种如权利要求1-19中任一项所述的药物组合物在制备治疗癌症的药物中的应用。
- 如权利要求20所述的应用,其特征在于:所述癌症为肺癌、胃癌、结直肠癌、宫颈癌、卵巢癌、前列腺癌、乳腺癌、胰腺癌、肝癌、膀胱癌、肾癌、骨癌、皮肤癌、黑色素瘤、神经胶质瘤、神经胶母细胞瘤、白血病或淋巴瘤,例如结直肠癌,例如结肠癌;和/或,PD-L1抗体和小分子PD-1/PD-L1抑制剂同时给药或分开给药;和/或,PD-L1抗体经注射给药;和/或,小分子PD-1/PD-L1抑制剂经口服给药。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11202110388VA SG11202110388VA (en) | 2019-03-22 | 2020-03-20 | Small-molecule inhibitor of pd-1/pd-l1, pharmaceutical composition thereof with pd-l1 antibody, and application of same |
CA3134171A CA3134171A1 (en) | 2019-03-22 | 2020-03-20 | Small-molecule inhibitor of pd-1/pd-l1, pharmaceutical composition thereof with pd-l1 antibody, and application of same |
AU2020246317A AU2020246317A1 (en) | 2019-03-22 | 2020-03-20 | Small-molecule inhibitor of PD-1/PD-L1, pharmaceutical composition thereof with PD-L1 antibody, and application of same |
EP20778787.0A EP3943083A4 (en) | 2019-03-22 | 2020-03-20 | SMALL MOLECULE PD-1/PD-L1 INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND USES THEREOF |
JP2021556946A JP2022527892A (ja) | 2019-03-22 | 2020-03-20 | 小分子pd-1/pd-l1阻害剤、pd-l1抗体との医薬組成物及びその使用 |
US17/441,410 US20220168268A1 (en) | 2019-03-22 | 2020-03-20 | Small-molecule inhibitor of pd-1/pd-l1, pharmaceutical composition thereof with pd-l1 antibody, and application of same |
KR1020217034418A KR20220004036A (ko) | 2019-03-22 | 2020-03-20 | 소분자 pd-1/pd-l1 억제제, 이와 pd-l1 항체의 약학 조성물 및 이의 용도 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910222624 | 2019-03-22 | ||
CN201910222624.0 | 2019-03-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020192570A1 true WO2020192570A1 (zh) | 2020-10-01 |
Family
ID=72563713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/080362 WO2020192570A1 (zh) | 2019-03-22 | 2020-03-20 | 小分子pd-1/pd-l1抑制剂、其与pd-l1抗体的药物组合物及其应用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220168268A1 (zh) |
EP (1) | EP3943083A4 (zh) |
JP (1) | JP2022527892A (zh) |
KR (1) | KR20220004036A (zh) |
CN (1) | CN111714628B (zh) |
AU (1) | AU2020246317A1 (zh) |
CA (1) | CA3134171A1 (zh) |
SG (1) | SG11202110388VA (zh) |
WO (1) | WO2020192570A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112121169B (zh) * | 2019-06-24 | 2023-10-24 | 广州再极医药科技有限公司 | 用于治疗具有高间质压力的肿瘤受试者的癌症的小分子抑制剂 |
US20230331675A1 (en) * | 2020-09-09 | 2023-10-19 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aromatic ethylene compound and preparation method therefor, and intermediate, pharmaceutical composition, and application thereof |
CN112724148B (zh) * | 2020-12-29 | 2022-04-12 | 上海药明康德新药开发有限公司 | 一种咪唑并哒嗪类化合物及修饰后的双亲功能分子及其应用 |
CA3242061A1 (en) * | 2021-12-24 | 2023-06-29 | Yuguang Wang | Aromatic vinyl compound, metal complex thereof, and preparation method therefor and use thereof |
WO2024175106A1 (zh) * | 2023-02-24 | 2024-08-29 | 广州再极医药科技有限公司 | Pd-l1小分子抑制剂与抗体的药物组合及其应用 |
CN116283953B (zh) * | 2023-03-10 | 2024-02-02 | 沈阳药科大学 | 含噻唑结构的吲哚啉类化合物及其制备方法和应用 |
Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015034820A1 (en) | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
CN104936982A (zh) * | 2012-08-03 | 2015-09-23 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017087777A1 (en) | 2015-11-19 | 2017-05-26 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017106634A1 (en) | 2015-12-17 | 2017-06-22 | Incyte Corporation | N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators |
WO2017112730A1 (en) | 2015-12-22 | 2017-06-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017202276A1 (zh) | 2016-05-23 | 2017-11-30 | 中国医学科学院药物研究所 | 苯醚类衍生物、及其制法和药物组合物与用途 |
WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017222976A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2018005374A1 (en) | 2016-06-27 | 2018-01-04 | Chemocentryx, Inc. | Immunomodulator compounds |
WO2018006795A1 (zh) | 2016-07-05 | 2018-01-11 | 广州再极医药科技有限公司 | 芳香乙炔或芳香乙烯类化合物、其中间体、制备方法、药物组合物及应用 |
WO2018009505A1 (en) | 2016-07-08 | 2018-01-11 | Bristol-Myers Squibb Company | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators |
WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2018026971A1 (en) | 2016-08-03 | 2018-02-08 | Arising International, Llc | Symmetric or semi-symmetric compounds useful as immunomodulators |
WO2018044783A1 (en) | 2016-08-29 | 2018-03-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2018051254A1 (en) | 2016-09-14 | 2018-03-22 | Aurigene Discovery Technologies Limited | Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators |
WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
WO2018119266A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
WO2018119224A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
WO2018195321A1 (en) | 2017-04-20 | 2018-10-25 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
CN110092740A (zh) * | 2018-01-29 | 2019-08-06 | 广州丹康医药生物有限公司 | 一种稠环化合物及其应用 |
CN110092745A (zh) * | 2018-01-29 | 2019-08-06 | 广州丹康医药生物有限公司 | 一种含芳环的化合物及其应用 |
CN110092779A (zh) * | 2018-01-29 | 2019-08-06 | 广州丹康医药生物有限公司 | 一种取代的苯基化合物及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202005962YA (en) * | 2017-12-29 | 2020-07-29 | Guangzhou Maxinovel Pharmaceuticals Co Ltd | Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application |
CN112121169B (zh) * | 2019-06-24 | 2023-10-24 | 广州再极医药科技有限公司 | 用于治疗具有高间质压力的肿瘤受试者的癌症的小分子抑制剂 |
-
2020
- 2020-03-20 US US17/441,410 patent/US20220168268A1/en active Pending
- 2020-03-20 AU AU2020246317A patent/AU2020246317A1/en not_active Abandoned
- 2020-03-20 SG SG11202110388VA patent/SG11202110388VA/en unknown
- 2020-03-20 JP JP2021556946A patent/JP2022527892A/ja not_active Withdrawn
- 2020-03-20 EP EP20778787.0A patent/EP3943083A4/en not_active Withdrawn
- 2020-03-20 WO PCT/CN2020/080362 patent/WO2020192570A1/zh unknown
- 2020-03-20 KR KR1020217034418A patent/KR20220004036A/ko unknown
- 2020-03-20 CN CN202010199836.4A patent/CN111714628B/zh active Active
- 2020-03-20 CA CA3134171A patent/CA3134171A1/en active Pending
Patent Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104936982A (zh) * | 2012-08-03 | 2015-09-23 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
WO2015034820A1 (en) | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017087777A1 (en) | 2015-11-19 | 2017-05-26 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017106634A1 (en) | 2015-12-17 | 2017-06-22 | Incyte Corporation | N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators |
WO2017112730A1 (en) | 2015-12-22 | 2017-06-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017202276A1 (zh) | 2016-05-23 | 2017-11-30 | 中国医学科学院药物研究所 | 苯醚类衍生物、及其制法和药物组合物与用途 |
WO2017202275A1 (zh) | 2016-05-23 | 2017-11-30 | 中国医学科学院药物研究所 | 溴代苄醚衍生物、及其制法和药物组合物与用途 |
WO2017202273A1 (zh) | 2016-05-23 | 2017-11-30 | 中国医学科学院药物研究所 | 苄苯醚类衍生物、及其制法和药物组合物与用途 |
WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2017222976A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2018005374A1 (en) | 2016-06-27 | 2018-01-04 | Chemocentryx, Inc. | Immunomodulator compounds |
WO2018006795A1 (zh) | 2016-07-05 | 2018-01-11 | 广州再极医药科技有限公司 | 芳香乙炔或芳香乙烯类化合物、其中间体、制备方法、药物组合物及应用 |
WO2018009505A1 (en) | 2016-07-08 | 2018-01-11 | Bristol-Myers Squibb Company | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators |
WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2018026971A1 (en) | 2016-08-03 | 2018-02-08 | Arising International, Llc | Symmetric or semi-symmetric compounds useful as immunomodulators |
WO2018044783A1 (en) | 2016-08-29 | 2018-03-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
WO2018051254A1 (en) | 2016-09-14 | 2018-03-22 | Aurigene Discovery Technologies Limited | Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators |
WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
WO2018119266A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
WO2018119224A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
WO2018195321A1 (en) | 2017-04-20 | 2018-10-25 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
CN110092740A (zh) * | 2018-01-29 | 2019-08-06 | 广州丹康医药生物有限公司 | 一种稠环化合物及其应用 |
CN110092745A (zh) * | 2018-01-29 | 2019-08-06 | 广州丹康医药生物有限公司 | 一种含芳环的化合物及其应用 |
CN110092779A (zh) * | 2018-01-29 | 2019-08-06 | 广州丹康医药生物有限公司 | 一种取代的苯基化合物及其应用 |
Non-Patent Citations (7)
Title |
---|
"Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH |
"Prodrugs: Challenges and Rewards", 2007, SPRINGER |
J. RAUTIO ET AL.: "Nature Reviews Drug Discovery", vol. 7, 2008, pages: 255 - 270 |
ONCOTARGET, vol. 8, 2017, pages 90215 - 90224 |
PROTEIN & CELL, vol. 9, no. 1, 2018, pages 135 - 139 |
See also references of EP3943083A4 |
TAD A. HOLAK: "J. Med. Chem.", vol. 60, 2017, UNIVERSITY OF JAGUARON, pages: 5857 - 5867 |
Also Published As
Publication number | Publication date |
---|---|
EP3943083A1 (en) | 2022-01-26 |
SG11202110388VA (en) | 2021-10-28 |
KR20220004036A (ko) | 2022-01-11 |
EP3943083A4 (en) | 2023-06-07 |
CA3134171A1 (en) | 2020-10-01 |
CN111714628A (zh) | 2020-09-29 |
US20220168268A1 (en) | 2022-06-02 |
JP2022527892A (ja) | 2022-06-07 |
AU2020246317A1 (en) | 2021-11-18 |
CN111714628B (zh) | 2024-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020192570A1 (zh) | 小分子pd-1/pd-l1抑制剂、其与pd-l1抗体的药物组合物及其应用 | |
JP7293560B2 (ja) | 芳香族ビニルまたは芳香族エチル系誘導体、その製造方法、中間体、薬物組成物および使用 | |
CN108299425B (zh) | 稠环衍生物、其制备方法、中间体、药物组合物及应用 | |
US20210387941A1 (en) | Diphenyl-like Compound, Intermediate Thereof, Preparation Method Therefor, Pharmaceutical Composition Thereof And Uses Thereof | |
TW201524958A (zh) | 用作轉染期間重排抑制劑之新穎化合物 | |
WO2016026445A1 (zh) | 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用 | |
JP2005521698A (ja) | 新規な三環式化合物 | |
WO2016169504A1 (zh) | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 | |
WO2021218755A1 (zh) | Shp2抑制剂及其组合物和应用 | |
WO2023098439A1 (zh) | 一种吡唑衍生物,其制备方法和在药学上的应用 | |
WO2020192650A1 (zh) | 酰胺类化合物制备方法及其在医药领域的应用 | |
WO2020020288A1 (zh) | 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途 | |
JP2022517730A (ja) | がんの処置のためのtgf-ベータr1(alk5)阻害剤としての(ピリジン-2-イル)アミン誘導体 | |
WO2022166860A1 (zh) | Pim激酶抑制剂 | |
WO2021227906A1 (zh) | 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途 | |
CN114269720A (zh) | 乙酰辅酶a合成酶短链2(acss2)的小分子抑制剂 | |
WO2020156162A1 (zh) | Mek抑制剂及其在医药上的应用 | |
WO2022268209A1 (zh) | 一种嘧啶并环结构衍生物及其用途 | |
TWI853806B (zh) | 小分子pd-1/pd-l1抑制劑、其與pd-l1抗體的藥物組合物及其應用 | |
WO2022089219A1 (zh) | 芳基酰胺化合物、包含其的药物组合物及其制备方法和用途 | |
JP7488768B2 (ja) | [1,2,4]トリアゾロ[4、3-a]ピラジン-8-オン誘導体 | |
WO2024093956A1 (zh) | 多环类聚(adp核糖)聚合酶选择性抑制剂 | |
WO2021057782A1 (zh) | 杂环衍生物及其用途 | |
WO2019154053A1 (zh) | Iap抑制剂及其在药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20778787 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3134171 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021556946 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020778787 Country of ref document: EP Effective date: 20211022 |
|
ENP | Entry into the national phase |
Ref document number: 2020246317 Country of ref document: AU Date of ref document: 20200320 Kind code of ref document: A |